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Preface
The In vitro neutralizing assays in Chapter 1 were conducted by Susana Pang in
Dr. John Schiller’s lab (Laboratory of Celluar Oncology, National Cancer Institute,
National Institute of Health). Sera used in this experiment were collected in
Michigan Technological University and were sent to our collaborator for further
studies. The HPV pseudovirus challenge experiments in Chapter 1 were
conducted by Julianne Peabody in Dr. Bryce Chackerian’s lab (Department of
Molecular Genetics and Microbiology, University of New Mexico School of
Medicine). The data were published in “Antiviral Research 147 (2017) 116-123”.
The Spray-freeze drying formulation into dry powder was conducted by Dr.
Nitesh Kunda in Dr. Pavan Muttil’s lab (Department of Pharmaceutical Sciences,
College of Pharmacy, University of New Mexico). We sent the liquid VLPs
samples to them and they sent us the lyophilized VLPs samples. Data in Chapter
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Abstract
Current human papillomavirus (HPV) vaccines (Cervarix and Gardasil-9) are
highly immunogenic and derived from the major capsid proteins (L1) of different
HPV types. L1 is not conserved among different HPV types. Thus, these L1based vaccines protect mostly against the HPV types included in the vaccines
with minimal cross-protection against non-vaccine HPV types. In addition to this,
the vaccines require refrigeration during transportation and storage. To broaden
protection against diverse HPV infection, we targeted epitopes (17-31, 69-86,
and 108-122) on the major capsid protein (L2) of HPV, which are conserved
among different HPV types for vaccine design. We explored the display of these
L2 epitopes, individually or as concatemers, on the surface of a highly
immunogenic bacteriophage MS2 virus-like particle (VLP) platform. VLPs are
empty viral shells without a viral genome. They are derived from viral structural
proteins such as envelope proteins or capsid proteins. VLPs cannot replicate,
they are non-infectious, and are highly immunogenic; thus, they are safe and
effective platforms for vaccine designs. Mice immunized with the MS2-L2
candidate HPV vaccine (a mixture of MS2 VLPs: one displaying a concatemer of
peptides from HPV16L2 & HPV31L2 and the other displaying a consensus
peptide, epitope 69-86, from the alignment of 23 HPV types) elicited high-titer
antibodies that protected mice from genital infection with nine diverse HPV types;
the VLPs also protected mice from oral infection with five diverse HPV types. To
ix

improve the thermostability of the MS2-L2 VLPs, the candidate vaccine was
formulated into powder by spray-freeze drying technique. Spray-freeze dried
VLPs stored at room temperature for two months were still immunogenic and
offered protection against HPV infection. Mixed MS2-L2 VLPs is a candidate next
generation HPV vaccine. We also explored, in this dissertation, the potential of
developing a novel thermostable VLP platform based on a thermophilic
bacteriophage, ΦIN93. Our results seem to suggest that co-expression of two
truncated versions of coat proteins from ΦIN93 have potential to form structures
that resemble VLPs.

x

Background
Immunity, vaccination and virus-like particles (VLPs):
The human body is well protected from infectious pathogens such as bacteria
and viruses by the complex immune system. The immune system is divided into
the innate immune system (innate immunity) and the adaptive immune system
(adaptive immunity). Innate immunity provides the first line of defense against
general pathogens. It does not show specificity to a particular antigen (antigenindependent), its response is immediate (from minutes to hours) after foreign
invasion, and it does not have memory responses. Three components provide
innate immunity: physical (skin) & chemical barriers (mucus, tears and saliva),
phagocytes (blood monocytes, neutrophils and macrophages), and pattern
recognition molecules [1]. When innate immunity fails to clear off invasions,
adaptive immunity is activated. Adaptive immunity has different features
compared to innate immunity: i) it takes longer time (several days) for the
response to be mounted; ii) it is more specific to the antigens (antigendependent); iii) it generates memory to the invaded pathogens, which means
adaptive immunity can rapidly recognize and response to the same antigens
following reinfection (with the same pathogen) with the help of the existing
memory cells or antibodies [2]. Adaptive immunity contains more complex
components such as T and B lymphocytes (T cells and B cells) and antibodies.
Antibody response or humoral immunity is one of the two main responses of
1

adaptive immunity (antibodies are produced by B cells). The other response, cellmediated immunity is mounted by T cells. As shown in Figure 1, the generation
and secretion of antibodies involves collaboration of a series of immune cells:
antigen-presenting cells (APCs) such as macrophages, B cells, and dendritic
cells ingest pathogens, digest the pathogens, and present antigens from the
pathogen, on cell surfaces in association with the major histocompatibility
complex (MHC) class ll molecules. CD4 T cells interact with APCs, which
displayed the antigens in association with MHC ll. CD4 T cells are then activated
and they release cytokines such as IL-4, IL-5 and IL-6. The released cytokines or
the cross-linking of B cell receptors can lead to B cells activation and
differentiation into plasma B cells (secrete antibodies) and memory B cells which
provide a rapid and long-lasting response on reinfection with the same pathogen
[3, 4]. Innate and adaptive immunities do not work independently, but rather are
complementary in maintaining host defense. While some pathogens can be
eliminated by the immune system, some will develop ways to escape from host
defense network to cause deadly diseases or cancers after infection. Thus,
vaccination became an important strategy to prevent some diseases and
cancers.

2

Fig. 1. Generation and secretion of antibodies through T cell and B cell
activation. Antigen invasion (green) can trigger phagocytosis whereby antigens
are phagocytosed and digested by antigen presenting cells (APCs). APCs then
display the processed antigens on surface together with MHC ll molecules.
Antigens on MHC II are presented to receptors on CD4 T cells causing CD4 T
cells activation. The activated CD4 T cells release cytokines to further activate
naïve B cells as well as the CD4 T cells. Activated B cells differentiate into
antibody secreting plasma cells (release antibodies against the antigen) and
3

memory B cells (for a rapid and effective response against reinfection with the
same antigen). In addition to this pathway, the antigens also can directly bind to
B cells by cross-linking with B cell receptors, leading to B cell activation. The
activated B cells differentiate into plasma cells. This type of B cell activation is
associated with little or no memory to the response.

Vaccination is defined as the administration of an antigen to the body to enable
the body to develop an immune response with the ultimate goal of to preventing
the body from being infected by the infectious agent from which the antigen was
derived. In other words, a vaccine is an imitation of real pathogen (organism) or
they are antigens derived from a pathogen but without the potential to infect or
cause a disease. They organism can be live but attenuated, it can be inactivated;
alternatively, the vaccine can be an antigen, which is a subunit or part of a real
pathogen or it could be a toxoid (non-toxic form of a toxin) derived from
pathogens; either of them can activate the host adaptive immune response to
offer protection against the real pathogen invasion [5, 6]. Adjuvants are often
used as part of a vaccine to enhance activation of the innate immune system and
thus protection. Diverse classes of compounds can be used as adjuvants
including aluminum salts, emulsions, saponins, liposomes and micro-particles [7].
Adjuvants can enhance the immune responses through diverse mechanisms
such as formation of a depot at the injection site for slow and constant
stimulation, up-regulation of cytokines & chemokines for recruitment of innate
4

immune cells, increase in antigen presentation to APCs, and activation and
maturation of APCs [8]. Safety and high immunogenicity are considered as two
important factors for developing a new vaccine. For example, attenuated
vaccines are highly immunogenic because the viruses are still alive and usually
one or two doses can achieve long-lasting protection; however, for people who
have weakened immune system or transplanted organs, live viruses might cause
diseases in vaccinees. The inactivated vaccines are safe for patients but need
more boosts to achieve and maintain a high level immunogenicity. Among all
these types of vaccines, multi-protein structured vaccines, based on virus-like
particles (VLPs) seem to be attracting a lot of attention as an approach in
developing next-generation preventive vaccines against infections agents [9].
VLPs are empty viral shells without viral genome formed by viral structural
proteins such as envelope proteins or capsid proteins. These structural proteins
can spontaneously assemble to form VLPs without the viral genomes; VLPs
therefore cannot replicate, they are non-infectious, and thus, they are safe for
vaccine designs. They are highly immunogenic; the sizes and the icosahedral
structures make them easy for APCs to recognize and take them up for
processing and antigen presentation to CD4 T cells. Also, repetitive copies of
antigens displayed on VLPs enable them to trigger strong immune responses
especially the cross-linking of B cell receptors on the surface of B cells. VLPs
have been used to develop vaccines against human papillomaviruses (HPVs)
[10, 11] and hepatitis B virus (HBV) [12]. VLPs derived from HPV are highly
5

immunogenic and protect against HPV-associated cancers (described in detail
below).
HPV, HPV vaccines, and limitations:
HPVs are non-enveloped DNA viruses, which infect human stratified epithelial
cells. More than 200 HPV types have been identified and among them, 42 types
are transmitted sexually [13, 14]. HPVs are the most common sexually
transmitted infections [15]. Ninety percent of HPV infections are cleared within 24
months after infection [16]. However, persistent infection with mucosal types can
lead to neoplasias [17]. HPV can be divided into two groups based on their
association with neoplasias: low-risk types and high-risk types. Infections with the
low-risk types (such as types 6, 11, 40, 42, 43, 44, 54, 61, 72, 81) are associated
with genital warts as well as recurrent respiratory papillomatosis (RRP). HPV
types 6 and 11 alone are associated with about 90% of genital warts and about
95% of RRP [18-21]. On the other hand, infections with the high-risk types (such
as 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 73, 82) are
associated with cancers such as cervical [18, 22], penile [23, 24], vulvar, anal,
and vaginal [25-27] cancers as well as head and neck squamous cell carcinomas
(including oral, oropharyngeal, and laryngeal cancers) [28].
Currently, two prophylactic vaccines, Cervarix (bivalent HPV), and Gardasil-9
(nonavalent HPV), have been approved by the Food and Drug Administration
(FDA) in the United States to protect against HPV infections [29]. These vaccines
6

are composed of virus-like particles (VLPs) derived from the major capsid protein
(L1) of HPV. The HPV vaccines are highly immunogenic. For example, as shown
in Figure 2, the Gardasil 9 protects against ~90%, worldwide average, of cervical
cancer cases caused by HPV16, 18, 31, 33, 45, 52, 58 and it also protects
against ~90% of genital warts cases caused by HPV6 and 11 [30]. Gardasil-9 is
also expected to protect against ~80-85% cases of HPV-associated vaginal
cancers, 90-95% of HPV-associated anal cancers, 85-90% of HPV-associated
vulvar cancers [30], and ~86% of penile cancers [24]. However, the current
vaccines still have some limitations.

Fig. 2. Worldwide estimated percentages of HPV-associated cancers, HPVassociated warts, and papillomatosis to be protected by Gardasil-9.
7

Estimates are based on the prevalence and the sum of percent contributions of
vaccine HPV types to different HPV-associated (cervical, vaginal, anal, vulvar,
penile, head and neck) cancers, genital warts including recurrent respiratory
papillomatosis. For example, 90% protection against cervical cancer is based on
the fact that HPV16 is associated with (~55.4%), HPV18 (16.1%), HPV45 (4.7%),
HPV31 (3.8%), HPV33 (4.1%), HPV52 (2.8%), and HPV58 (3.0%) of cervical
cancer cases worldwide.

First, they offer protection mostly against HPV types included in the vaccines but
with less or no protections against non-vaccine HPVs. This is because they are
derived from L1 proteins, which are not conserved among HPV types; they
protect mostly against the HPV types included in the vaccines with little crossprotection against non-vaccine HPV types (e.g. HPV31, 45, 58) [31-35]. People
who are infected with HPV, especially HIV patients, are able to be infected with
multiple HPV types: up to 10 HPVs were found in one HIV-infected patient [36].
Thus, an optimal HPV vaccine should protect against more cancer-causing HPVs
to decrease the risk of developing HPV-associated cancers. Secondly, since little
is known about the ability of current vaccines to protect against oral HPV
infections, it is important and necessary to go further to study the efficacy of the
vaccine against diverse oral HPVs infections. Thirdly, the current vaccines are
thermosensitive; thus, refrigeration and temperature monitoring facilities are
required for the vaccines. Refrigeration equipment is not available worldwide
8

especially in the developing countries and regions, where there are higher rates
of HIV infections.

Fig. 3. HPV genome and capsid structure model. HPV genome is circular, but
it is shown in the linear form (top image) for simplicity. Genes coding for early
proteins (E1, E2, E4, E5, E6 and E7), which are non-structural proteins are
shown in green. Genes coding for late proteins are L1 and L2; L1 (shown in blue)
forms pentamers and each pentamer has one L2 (shown in red) at the vertex of

9

each pentamer. The icosahedral capsid (bottom; surrounds the genome) is
composed of major capsid protein (L1) and minor capsid protein (L2).

With this in consideration, other studies have been looking into designing a next
generation HPV vaccine, targeting the minor capsid protein, L2, shown in Figure
3. The minor capsid protein, especially the N-terminus, is highly conserved
among diverse HPV types [37, 38]. Nevertheless, normal infection does not
induce protective anti-L2 antibody responses because L2 is only transiently
exposed on the capsid. During HPV infection, the capsid binds to heparan sulfate
proteoglycan (HSPG) on the basement membrane; the capsid then undergoes a
series of conformational changes thus transiently exposing the N-terminal portion
of L2 [39, 40]. This conformational change allows the virus to bind to and infect
epithelial cells. If neutralizing antibodies, following immunization with L2 antigens
are available, they can bind to exposed-neutralizing L2 epitopes thus preventing
the infection [39, 40] (Fig. 4). Neutralizing L2 antibodies can cross-protect against
diverse HPV types [41-43].The L2 protein, unlike the L1 protein, cannot form
VLPs and thus, it is less immunogenic. Thus, different approaches have been
explored to enhance the immunogenicity of L2 protein; these include conjugation
of an L2 peptide to thioredoxin [44, 45], construction of L2 concatemer proteins
derived from different HPV types [46, 47], and the display of L2 peptides on
different types of VLPs [48-52]. While these approaches enhance crossprotection against diverse HPV types, they do not offer complete protection
10

against all cancer-causing HPV types. VLPs derived from viruses that infect
bacteria (bacteriophages e.g. MS2, PP7 and QB) have also been used as
platforms to multivalently display less immunogenic peptides from other
pathogens in order to increase the immunogenicity of the peptides [49, 53]. In
this dissertation, I focused on developing a candidate L2 vaccine against HPV
based on a bacteriophage MS2 VLP platform. In addition to this, I explored the
potential to develop a novel thermostable VLP platform based on a virus, ΦIN93,
which infects a thermophilic bacterium.

Fig. 4. Schematic (adapted from [39]) illustrating HPV infection and how L2
antibodies targeting L2 protein prevents HPV infection. Micro-trauma or a cut
allows HPVs to: 1) bind to heparan sulfate proteoglycan (HSPG) on basement
membrane cells. 2) After conformational change, pre-buried L2 will be shortly
exposed and cleaved for another conformational change, which allows the
viruses to 3) recognize receptors (integrin proteins) on epithelial cells and
11

infection of the cells are initiated. 4) In the presence of anti-L2 antibodies, binding
to the receptor is blocked and infection is prevented.

12

Special aims
The goals of my dissertation were to develop a candidate prophylactic HPV
vaccine, which can protect against more high-risk HPVs infections (including
protection from oral HPV infections) and to formulate the candidate vaccine into a
thermostable product that can be transported and stored without the need to
refrigerate the vaccine. In a previous study, an HPV16 L2 epitope containing
amino acids (aa) 17-31 displayed on MS2 bacteriophage VLPs offered protection
against up to 11 HPV types (HPV5, 6, 16, 31, 33, 35, 39, 45, 51, 53, and 58) [49].
However, there was suboptimal protection against some of these HPVs including
those associated with HNCs. To broaden and enhance protection, in this
dissertation, we attempted to display more epitopes on the same VLPs already
displaying

HPV16

L2

epitopes.

Additionally,

we

assessed

oral

immunity/protection following oral immunization with our L2 phage VLPs together
with a combination of different mucosal adjuvants. Furthermore, we used sprayfreeze drying technique to convert the liquid VLPs into a thermostable dry
powder vaccine. We also assessed whether coat proteins from a thermophilic
phage ΦIN93 can assemble into VLPs. Our hypotheses are: i) immunization with
multi-epitope L2 VLPs can offer broader protection against more HPV types; ii) a
spray-freeze dried VLPs powder vaccine will be more stable for storage at room
temperature; iii) coat proteins of ΦIN93, expressed in E. coli, can assemble into
VLPs.
13

Aim 1) Develop and test a candidate vaccine with multiple epitopes displayed on
MS2 bacteriophage VLPs. Sequences of all high-risk HPVs and some wartcausing low-risk HPVs were aligned and two consensus epitopes that have the
potential to broaden protection against diverse HPVs were chosen and used to
design a candidate HPV vaccine (Chapter 1).
Aim 2) Assess the ability to enhance oral immune response using a combination
of mucosal adjuvants. Mucosal adjuvants such as cholera toxin (CT) and
monophosphoryl lipid A (MPLA) are able to stimulate signaling pathways
associated with immune responses and thus they may enhance oral immune
responses (Chapter 2)
Aim 3) Use the spray-freeze drying technique to formulate L2 vaccine
with/without mucosal adjuvants to a thermostable powder. This strategy can
avoid the problems of vaccine refrigeration during transportation and storage in
developing countries (last part of Chapter 2)
Aim 4) Develop a novel VLP platform based on thermophilic bacteriophage
ΦIN93 coat proteins (Chapter 3)
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Chapter 1
A Novel Candidate MS2 Phage VLP Vaccine Displaying a
tandem HPV L2 Peptide offers Similar Protection in Mice
to Gardasil-9
1.1 Abstract
Human papillomaviruses (HPVs) cause approximately 5% of cancer cases
worldwide. Fortunately, three prophylactic vaccines have been approved to
protect against HPV infections. Gardasil-9, the most recent HPV vaccine, is
predicted to offer protection against the HPV types that cause ~90% of cervical
cancer, 86% of HPV-associated penile cancers, and ~93% of HPV-associated
head & neck cancers. As an alternative to Gardasil-9, we developed and tested a
novel candidate vaccine targeting conserved epitopes in the HPV minor capsid
protein, L2. We displayed a tandem HPV31/16L2 peptide (amino acid 17-31) or
consensus peptides from HPV L2 (amino acid 69-86 or 108-122) on the surface
of bacteriophage MS2 virus-like particles (VLPs). Mice immunized with the MS2
VLPs displaying the tandem peptide or immunized with a mixture of VLPs
(displaying the tandem peptide and consensus peptide 69-86) elicited high titer
antibodies against individual L2 epitopes. Moreover, vaccinated mice were
protected from cervicovaginal infection with HPV pseudoviruses 16, 18, 31, 33,
45, and 58 at levels similar to mice immunized with Gardasil-9. These results
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suggest that immunization with a tandem, L2 peptide or a low valency mixture of
L2 peptide-displaying VLPs can provide broad protection against multiple HPV
types.

1.2 Introduction
Human papillomaviruses (HPVs) are the most common sexually transmitted
infections; approximately 40 HPV types can be transmitted sexually and they
cause neoplasias such as genital warts and cancers [1, 2]. Persistent infection
with high-risk HPV (HR-HPV) types (HPV16, 18, 26, 31, 33, 35, 39, 45, 51, 52,
53, 56, 58, 59, 66, 70, 73, 82) is associated with ~94% of anal cancers, ~63% of
penile cancers, ~74% of vaginal cancers, ~5-20% of head & neck squamous cell
carcinomas, and nearly all cases of cervical cancers [3-5]. Infections with low-risk
HPV types (HPV6, 11, 43, and 44) are associated with genital warts [6-8]. HPVassociated cancers can be initiated by infection with a single HR-HPV type or by
infection with multiple HR-HPV types [9, 10]; a situation that occurs especially in
human immunodeficiency virus (HIV) and acquired immunodeficiency syndrome
(AIDS) patients. HIV/AIDS patients are more susceptible to HPV-associated
cancers compared to non-HIV infected patients [9, 11-15]. Thus, these patients
need broad protection from infections by multiple HPV types.
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Two prophylactic vaccines (Cervarix, and Gardasil-9) have been approved
to protect against certain types of HPV infections. The vaccines are composed of
virus-like particles (VLPs) derived from HPV major capsid protein (L1). The
vaccines are highly immunogenic. However, because L1 neutralizing epitopes
are not highly conserved among HPV types, L1 vaccines protect mostly against
the HPV types included in the vaccines, with minimal cross-protection against
non-vaccine HPV types [16-20]. For example, Gardasil-9 offers protection
against the HR-HPV types (HPV16, 18, 31, 33, 45, 52, 58) that cause ~93% of
head and neck cancers, ~90% of cervical cancers, 90-95% of anal cancers and
more than 80% of vaginal, penile and vulvar cancers. The vaccine also protects
against HPV6 and 11, types that cause 90% of genital warts. [4]. As such,
women who are vaccinated with Gardasil-9 vaccine (and also the other HPV
vaccines) are still advised to continue screening for other HPV types not included
in the vaccine. To broaden protection, researchers have focused on developing
next-generation HPV vaccines targeting the HPV minor capsid protein (L2) [2123]. The minor capsid protein, especially the N-terminus, is highly conserved
among diverse HPV types [24, 25]. Nevertheless, normal infection does not
induce protective anti-L2 antibody responses because L2 is only transiently
exposed on the capsid. During HPV infection, the capsid binds to heparan sulfate
proteoglycan (HSPG) on the basement membrane; the capsid then undergoes a
series of conformational changes thus transiently exposing the N-terminal portion
of L2 [26, 27]. This conformational change allows the virus to bind to and infect
epithelial cells. If neutralizing antibodies, following immunization with L2 antigens
22

are available, they can bind to exposed-neutralizing L2 epitopes thus preventing
the infection [26, 27]. Neutralizing L2 antibodies can cross-protect against
diverse HPV types [28-30]. However, L2-based immunogens generally elicit
much lower antibody titers than L1 VLPs because, unlike L1, L2 cannot selfassemble into VLPs. Different approaches have been explored to enhance the
immunogenicity of L2 protein; these include conjugation of an L2 peptide to
thioredoxin [21, 31], construction of L2 concatemer proteins derived from
different HPV types [22, 32], and the display of L2 peptides on different types of
VLPs [33-37]. While these approaches enhance cross-protection against diverse
HPV types, they do not offer complete protection against all cancer-causing HPV
types. In a previous study, we displayed a conserved epitope (representing
amino acid 17-31) from HPV16 L2, on the surface of bacteriophage MS2 VLPs.
MS2-16L2 VLPs elicited strong antibody response in mice and offered complete
protection against HPV16 pseudovirus (PsV) 16 as well as sub-optimal crossprotection against other HPV PsV types [34]. In another study, we showed that
immunization with bacteriophage VLPs displaying a consensus L2 epitope
(representing amino acid 65-85 derived from an alignment of different HR-HPV
types), enhanced cross-neutralization, albeit at low titers, against diverse HPV
PsV types (PsV 16, 31, 18, 45 and 58) compared to immunization with VLPs
displaying a similar epitope derived from HPV16 [36]. These results suggested
that the immunogenicity as well as the spectrum of protection against diverse
HPV types could be enhanced by displaying conserved or consensus L2
epitopes on the surface of bacteriophage VLPs. In this study, we assessed the
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spectrum of protection against diverse HPV types following immunization with a
mixture of two MS2-L2 VLPs in comparison to immunization with Gardasil-9.

1.3 Materials and methods
1.3.1 Cloning, expression and purification of MS2-L2 VLPs
Polymerase chain reaction (PCR) was used, as previously described [38], to
insert different HPV L2 epitopes on the N-terminus of the single-chain dimer of
MS2 bacteriophage coat protein. Plasmid pDSP62 (which expresses the singlechain dimer of MS2 coat protein) was used as a PCR template (Fig. 1).

Fig. 1. Schema showing insertion of 16 L2 epitope at N-terminus of MS2
bacteriophage and assembly of VLPs.
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To get a consensus L2 sequence, amino acid sequences of all HR-HPVs and
some low-risk ones (HPVs 6, 11, 34, 43 and 59) were analyzed and aligned by
Jalview software and T-coffee program (Fig. 2). The following HPV L2 peptides
(Table 1) representing amino acids (aa) sequences were inserted: a tandem
peptide (aa 20-31 from HPV31 L2 & aa 17-31 from HPV16 L2), aa 69-86 from a
consensus (cons)L2 sequence, aa 108-122 from a consensus (cons)L2
sequence, and a multivalent epitope representing consL2(108-122)/HPV31L2
(20-31)/HPV16L2(17-31).
These L2 sequences were engineered into forward PCR primers. A reverse
primer, E3.2 (5′ CGGGCTTTGTTAGCAGCCGG 3′), which anneals downstream
of a unique BamHI site in the pDSP62 plasmid was used for all PCR
amplifications above. Amplified MS2-L2 PCR fragments were cloned into
pDSP62 plasmid using NcoI and BamHI restriction sites and the plasmids were
then transformed into C41 E. coli bacteria. All constructs were sequenced to
confirm insertions. To express recombinant MS2-L2 proteins, transformed C41
cells were grown at 37oC until the cells reached an optical density (OD)600 of 0.6.
Protein

expression

was

induced

with

0.5

mM

isopropyl

β-D-1-

thiogalactopyranoside for 4 hours or overnight. Cell pellets were collected and
lysed using 0.2% lysozyme solution. Soluble MS2-L2 VLPs were purified by gel
filtration on Sepharose CL-4B column.
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1.3.2

Characterization of MS2-L2 VLPs

Transmission electron microscopy (TEM) was used to assess whether all
constructs assembled into VLPs in a way as previously described [38]. To
examine whether the L2 epitopes were displayed on the MS2 bacteriophage
VLPs, enzyme-linked immunosorbent assay (ELISA) and Western blot were
performed. Western blotting was conducted as follows: 100 ng of MS2-L2 VLPs
or control MS2 VLPs were run on an SDS-PAGE gel and transferred to
polyvinylidene fluoride membranes. The membranes were blocked and 1:5,000
dilution of anti-HPV16 L2 (aa 1-88) serum [34] or MS2 serum was added and
incubated for 2 hours. The membranes were washed and 1:10,000 dilution of
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horseradish peroxide (HRP)-conjugated goat anti-mouse IgG antibodies added
for 1 hour. The membranes were then washed and developed using a mixture of
SuperSignal West Pico (Lumino/Enhance and Stable Peroxide) solutions. To
confirm the Western blot results, ELISA was conducted as follows: Briefly, ELISA
plates were coated with 500 ng of purified MS2-L2 VLPs. The wells were blocked
and serial dilutions of anti-HPV16 L2 (aa 1-88) serum was added. The plates
were incubated for 2 hours and 1:5,000 dilution of HRP-conjugated goat antimouse IgG antibodies was added for 1 hour. The plates were developed by
adding 3, 3', 5, 5'-tetramethylbenzidine (TMB) and the reactivity was determined
at OD450.

1.3.3 Immunization of mice and characterization of antibody responses
All animal work was conducted in accordance with Institutional Animal Care and
Use Committee (IACUC) guidelines. Four Balb/c mice (per group) were
immunized intramuscularly (i.m.) with 5µg each of MS2-16L2 VLPs (displaying aa
17-31 from HPV16) [34], MS2-31L2 VLPs (displaying aa 17-31 from HPV31) [36],
MS2-31/16L2 VLPs (displaying tandem L2 peptide 20-31 and 17-31 from HPV31
and HPV16, respectively), MS2-consL2(69-86), MS2-consL2(108-122), MS2consL2(108-122)/31L2/16L2, or immunized with a mixture of VLPs [Mixed MS2L2 VLPs: 5µg MS2-consL2(108-122)/31L2/16L2 plus 5µg of MS2-consL2(6986)]. All VLPs were mixed with alum hydroxide adjuvant prior to immunizations
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and immunizations were done twice at two-week intervals. Anti-L2 IgG antibody
responses in sera were tested by L2 peptide-ELISA using synthetic HPV16L2
(17-31), HPV31L2 (17-31), consL2(69-86), and consL2(108-122) as target
antigens. The peptides were conjugated to streptavidin using biotin or SMPH
[Succinimidyl 6-((beta-maleimidopropionamido)hexanoate)] and were then used
to coat ELISA plates. ELISAs were conducted as described above and the titers
of antibodies were determined as the reciprocal of the highest sera dilution with
an OD450 greater than 2-fold compared to that of control sera at the same
dilution.

1.3.4 Pseudovirus production and purification
HPV PsV types (PsV: 16, 33, 45, 58) encapsidating a reporter plasmid [pClucf:
encodes both green fluorescence protein (GFP) and luciferase] were produced in
293TT cells as previously described [39]. Briefly, 293TT cells were transfected
with a mixture of two plasmids (each HPV shell and a pCluf). Forty-eight hours
after transfection, cells were lysed and mature PsV was purified on a cesium
chloride gradient by ultracentrifugation at 20,000 rpm for 17 hours or 40,000 rpm
for 4 hours.
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1.3.5 Cervicovaginal infection with HPV PsVs
Mice were intramuscularly immunized twice each with 5 µg of MS2 control VLPs,
MS2 VLPs displaying L2 peptides or with Mixed MS2-L2 VLPs at two-week
intervals. In addition to these, another group of mice was immunized with 5 µg of
Gardasil-9. All immunizations were done with alum hydroxide adjuvant. Two
weeks after the last immunization, mice were subcutaneously treated with 3mg of
Depo-Provera. After five days, mice were vaginally challenged with ~6.4 x 106
infectious unit (IU) of PsV. Forty-eight hours post-PsV challenge, mice were
vaginally instilled with 0.4 mg of luciferin and imaged with a Caliper IVIS Lumina
II as previously described [38].

1.3.6 In vitro neutralization assays
Neutralization assays were performed as previously described [40]. Briefly, HPV
PsV18 and PsV33 encapsidating a reporter plasmid (pfwB: expresses GFP) were
made in 293TT cells as above. HPV PsV18 and PsV33 were titered in pgsa-745
cells and virus titers that lead to 20% and 75% infectivity (expression of GFP
relative to control cells), respectively, were used in the neutralization assay as
followings: extracellular matrix (ECM) from MCF10A cells was deposited in 96well plates followed by the addition of the PsVs. The ECM-PsVs were incubated
overnight followed by the addition of serial-dilutions of sera collected from
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immunized mice or addition of growth media as control. The plates were
incubated for 6 hours and pgsa-745 cells were added. Forty-eight hours later,
PsV infectivity/neutralizations were assessed by flow cytometry based on the
expression levels of GFP in infected cells. The reciprocal of the highest sera
dilution that inhibited 50% of PsV infection relative to control sera was considered
the neutralization titer.

1.3.7 Statistical analysis
Statistical analyses for ELISA and PsV challenges were determined by unpaired
two-tailed t-test and unpaired one-tailed t-test, respectively.

1.4 Results
1.4.1 Insertion of multiple L2 epitopes on MS2 coat protein does not affect
VLP assembly
We had previously shown that immunization with MS2 bacteriophage VLPs
displaying HPV16L2 (17-31) offered complete protection against HPV PsV16 but
suboptimal cross-protection against other high-risk HPV PsV types. To enhance
protection against these other HPV types, we explored several strategies. First,
we constructed recombinant coat proteins displaying a tandem L2 peptide (aa
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20-31 from HPV31 and aa 17-31 HPV16) or consensus L2 sequences
(representing aa 69-86 or aa 108-122) at the N-terminus of the MS2 coat protein.
The consensus sequence was obtained by aligning amino acid sequences from
19 HR-HPV types plus 4 low-risk types using Jalview software (version 2.9.0b2)
and T-coffee program (Fig. 2). In a second strategy, we inserted multiple
epitopes [consL2(108-122) and the tandem 31L2/16L2 peptide] on the MS2 coat
protein.

Fig. 2. Consensus sequence of HPVs L2 proteins. Consensus sequences
were obtained by aligning HR-HPV types (HPVs 16, 18, 26, 31, 33, 34, 35, 39,
45, 51-53, 56, 58, 59, 66, 68, 73 and 82) and low-risk HPV types (HPVs 6, 11,
43, and 44) using Jalview software (http://www.jalview.org/) and T-coffee
program (an plugin of Jalview software). Highly conserved amino acids
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(conservation) are shown in yellow/gold tall bars whereas less conserved amino
acids are shown in tan/chocolate short bars. Glycine (G) at position 85 was not
included in designing consensus (69-86) peptide because only HPV 11 had G at
this position. “+” at position 114 was replaced with valine (V) since most HPVs
have V at this site. Glutamic acid (E) at 116 and Alanine (A) at 121 were replaced
with isoleucine (I) and proline (P), respectively.

The results of TEM analysis indicated that proteins produced from all these
recombinant constructs assembled into VLPs (Fig. 3 and Table 1).
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Fig. 3. Transmission electron microscopy (TEM) images of MS2-L2 VLPs
that were assembled from recombinant proteins containing various L2
epitopes. All images were taken at magnification of 70,000X.

To confirm that the coat proteins contained L2, VLPs were analyzed by Western
blot using anti-MS2 and anti-HPV16 L2 (aa 1-88) serum. As shown in Fig. 4A,
anti-HPV 16L2 serum reacted with all VLPs except with MS2-consL2(108-122)
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and control MS2 VLPs as expected. As expected, anti-MS2 serum reacted with
each VLP. The varying sizes of recombinant MS2-L2 protein bands reflect the
differences in the sizes of inserted L2 epitopes.

Fig. 4. Characterization of L2 peptides on MS2 VLP. A) Reactivity of HPV16
L2 (aa 1-88) serum and MS2 serum with MS2-L2 VLPs or MS2 VLPs in Western
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blots. One hundred ng of VLPs were loaded to 10% SDS-PAGE gel and 16L2 (188) serum (top) and MS2 serum (bottom) were used as primary antibodies at a
dilution of 1:5,000. B) Reactivity of HPV16 L2 (aa 1-88) serum with MS2-L2 VLPs
or MS2 VLPs. ELISA plates were coated with 500 ng of VLPs and reacted with
the serum at a dilution of 1:10,240 (left) and 1:640 (right). The average ODs450
for 4 mice are shown. Error bars stand for standard error of the mean (SEM).

To assess if the L2 peptides were actually displayed on intact VLPs, an ELISA
was conducted using MS2-L2 VLPs or control MS2 VLPs as target antigens. As
shown in Fig. 4B, anti-HPV16 L2 serum (at a 1:10,240 dilution) reacted with
MS2-31/16L2 VLPs and MS2-consL2(108-122)/31L2/16L2 VLPs, and, to a lesser
extent (at a 1:640 dilution) with MS2-consL2(69-86) VLPs. These data suggest
that the peptides are displayed on the surface of VLPs.

1.4.2 MS2 VLPs displaying multiple L2 epitopes are immunogenic
To assess the immunogenicity of MS2 VLPs displaying the L2 peptides, mice
were immunized with two doses (5 µg/dose) of purified MS2-L2 VLPs or control
MS2 VLPs. Another group of mice was immunized twice with a mixture of VLPs
[Mixed MS2-L2 VLPs; MS2-consL2(108-122)/31L2/16L2 plus MS2-consL2(6986)] in order to assess whether immunizing with multiple L2 VLPs could enhance
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the spectrum of protection. In general, all of the VLPs elicited high-titer antibody
responses.

Sera collected from mice immunized with MS2-16L2, MS2-31L2,

MS2-31/16L2, and MS2-consL2(108-122)/31L2/16L2 VLPs had high antibody
titers (>104) against HPV16 and HPV31 L2 peptides (Figs. 5A-B). Moreover,
mice immunized with MS2-consL2(69-86) VLPs had high IgG titers against
consL2(69-86) peptide (Fig. 5C). In contrast, VLPs displaying the consL2(108122) peptide were less immunogenic and induced lower antibody titers (<103)
(Fig. 5D). Mice immunized with Mixed MS2-L2 VLPs had similar antibody titers
(>104) against HPV16 L2, HPV31 L2 and consL2(69-86) peptides as mice
immunized with individual VLPs (Figs. 5A, B and C), suggesting that mixing the
VLPs did not compromise the immunogenicity of individual L2 epitopes.
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Fig. 5. Immunogenicity of MS2-L2 VLPs in mice. Mice were immunized twice
with 5 µg of MS2-L2 VLPs or control MS2 VLPs at two-week intervals. Sera were
collected two weeks after the last immunization and anti-L2 peptide IgG titers
were determined by end-point dilution ELISA using: A) 16L2 (17-31) peptide, B)
31L2 (17-31) peptide, C) consensus L2(108-122) peptide, and D) consensus
L2(69-86) peptide as target peptides. Titers were determined as the reciprocal of
highest sera dilutions at which reactivity of experimental sera was at least twice
that of control MS2 sera. “Mixed MS2-L2 VLPs” serum was collected from mice
immunized with a mixture of consL2(108-122)/31L2/16L2 and consL2(69-86)
VLPs. Each datum (circles, squares, rectangles, and triangles, etc.) represents
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titer in an individual mouse and lines stand for the geometric mean for each
group.

1.4.3 MS2 VLPs displaying multiple L2 epitopes offered broad protection
against HPV PsVs, at levels similar to Gardasil-9 vaccine
To determine whether immunization with MS2-L2 VLPs conferred protection from
genital infection with various HPV types, immunized mice were vaginally infected
with HPV PsV (16, 31, 45, and 58) and protection efficacies were compared to
those of mice immunized with Gardasil-9 or control MS2 VLPs. We assessed
cross-protection against HPV PsV31 and 58 because in a previous study [34] we
observed suboptimal cross-protection against these PsVs following immunization
with MS2-16L2 VLPs. Mice immunized with MS2-16L2, MS2-31L2, MS231/16L2, MS2-consL2(108-122)/31L2/16L2, and Mixed MS2-L2 VLPs showed
protection against HPV PsV31, at levels similar to Gardasil-9 (which contains
HPV31 VLPs) vaccine-immunized mice (Fig. 6A); Moreover, almost complete
protection were observed against PsV58, PsV45, and PsV16 challenge (Figs.
6B-6D). Mice immunized with MS2-consL2(69-86) VLPs showed only slight
protection (not significant) against the HPV PsV types tested, and MS2consL2(108-122) was not protective. Mixed MS2-L2 VLPs offered the best
protection

against

all

PsV

types
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except

against

PsV58.
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Fig. 6. Mice immunized with MS2-L2 VLPs elicit protective antibody
responses against HPV PsV31, 45, 58, and 16. Mice vaccinated with MS2-L2
VLPs or MS2 control VLPs were vaginally challenged with ~6.4 x 106 IU of HPV
PsVs. Forty-eight hours post-challenge, luciferin was instilled vaginally and
images were taken 3 minutes post-luciferin instillation except in 4A were images
were taken 10 minutes post-luciferin instillation. The average radiance
(p/s/cm2/sr) of luciferase expression at the genitals was determined using Living
Image 3.2 software. Each datum represents the radiance value of an individual
mouse and the lines stand for the average geometric mean for each group. Red
dashed lines highlight MS2-L2 VLPs efficacy in comparison to Gardasil-9
vaccine.

The in vitro neutralization assay is an alternative method that can be used
to test the neutralization efficacy (i.e. predict protection potentials) of candidate
HPV vaccines. To test the neutralizing potential of our MS2-L2 VLPs with other
HPV types, sera from mice immunized with VLPs (MS2-31/16L2 and Mixed MS2L2) that offered the best protection against vaginal infection were used in an in
vitro neutralization assay against PsV18 and PsV33. Compared to control MS2
sera, sera from mice immunized with MS2-31/16L2 or Mixed MS2-L2 VLPs
neutralized PsV18 and PsV33 at levels similar to sera from mice immunized with
Gardasil-9 (Fig. 7). These results show that MS2-31/16L2 and Mixed MS2-L2
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VLPs sera are protective in vivo and in vitro against infection by diverse HPV
types.

Fig. 7. MS2-L2 sera neutralize HPV PsV18 and PsV33. Titers of HPV PsV18
and PsV33 that led to 20% and 75% infectivity, respectively, of pgsa-745 cells
were separately incubated with serial-dilutions of sera collected from mice
immunized with MS2-L2 VLPs or controls. Incubated PsV and sera were then
used to infect pgsa-745 cells. Forty-eight hours after infection, PsV neutralization
(based on GFP expression levels) was determined by flow cytometry. Bars
indicate the reciprocal of the highest sera dilution at which at least 50% HPV PsV
was neutralized compared to controls with no sera. MS2 control sera neutralizing
titers were <50.
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1.5 Discussion
Current HPV vaccines protect mostly against the HPV types included in
the vaccines [4]. Given the fact that protection from HPV infections is not 100%,
patients vaccinated with any of the HPV vaccines are still recommended to
continue cervical cancer screening. The recommended screening is very crucial
for HIV/AIDS patients given the immunocompromised nature of their immune
system, their propensity to be co-infected with up to 10 HR-HPV types [12, 13],
and the risk for their HPV infections to progress to invasive cancer 6 to 15 years
earlier than non-HIV patients [41, 42]. Thus, there is a need to develop an HPV
vaccine with the potential to offer complete protection against HPV-associated
cancers, especially in HIV/AIDS patients. We had previously reported that a
thermostable bacteriophage MS2 VLPs displaying peptide 17-31 from HPV16
offered complete protection against HPV PsV16 and other HPV PsVs, but
suboptimal protection against two important heterologous HPV types (HPV31
and HPV58) [34, 43]. To enhance protection against some of these heterologous
HPV types, we generated for the first time, VLPs [MS2-31/16L2 and MS2consL2(108-122)/31L2/16L2] displaying concatemers of two or three L2 epitopes,
respectively. In addition to these, we developed VLPs [MS2-consL2(69-86),
MS2-consL2(108-122)] displaying consensus sequences. Anti-HPV16 L2 serum
reacted with all the MS2-L2 VLPs (confirming display of peptides on VLPs)
except for VLPs displaying consL2(108-122) (Figs. 2A and 2B). Lack of reactivity
with MS2-consL2(108-122) VLPs was expected because the HPV16 L2 (aa 1-88)
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serum does not include consL2(108-122) epitope. The reactivity of anti-HPV16
L2 serum with MS2-consL2(69-86) VLPs (compared with other L2-VLPs) was
low. This could be explained by the fact that HPV16 L2, from which the serum
was generated is 80% identical to 31L2 (at aa 17-31) unlike peptide 69-86 of
HPV16 L2, which is only 72% identical to consL2(69-86).
Mice

immunized

with

VLPs

displaying

concatemers,

consensus

sequences [except MS2-consL2(108-122)], and Mixed MS2-L2 VLPs [MS2consL2(108-122)/31L2/16L2 plus MS2-consL2(69-86)]

elicited high anti-L2

antibody titers (Fig. 3), which protected/neutralized six HPV PsV types (16, 18,
31, 33, 45, 58) at levels similar to Gardasil-9 vaccine (Figs. 4 and 5). Mixed MS2L2-immunized mice offered the best protection except against PsV58; we are not
sure why partial protection was observed given the fact that 31L2 and 16L2 (1731) share ~87% and 80% amino acid identity, respectively, with 58L2 at the
same epitope. MS2-16L2 VLPs in this study offered good protection (although a
little less compared to MS2-31L2 VLPs) against PsV31 and PsV58, whereas we
had observed less protection in a previous study [34]. It is likely that mice in our
previous study were challenge with higher PsV dose compared to this study. For
example, control MS2 mice challenged with PsV31 in our previous study had a
higher geometric mean average radiance (GMAR 105.5) compared to MS2 control
mice in this study with GMAR of 104.8. Irrespective of thesedifferences, these
results suggest that immunization with a tandem L2 peptide or a mixture of L2
peptides does not compromise the immunogenicity of individual epitopes.
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While robust responses were observed with the VLPs displaying peptide
17-31 (single or tandem peptide), little protection was observed in mice
immunized with VLPs displaying peptide consL2(69-86) and no immune
responses were observed in mice immunized with VLPs displaying peptide
consL2(108-122). It was surprising that no significant protection was observed in
mice immunized with the MS2-consL2(69-86) given the fact that mice had high
anti-L2 antibody titers against this peptide. A previous study had shown that sera
(at 1:1000 dilution) from mice immunized with Qβ bacteriophage VLPs displaying
a similar conjugated consensus L2 peptide neutralized HPV PsV31, 45, 58 [36].
The discrepancy in the results could be explained by the fact that the previous
study used a slightly longer consensus sequence (65-85), which included 4
additional amino acids (GTGG) that are highly conserved amongst HPV types.
We attempted here to insert (genetically) the same epitope on the coat protein of
MS2; however, no expression of the fusion protein was detected (data not
shown). With respect to consensus peptide 108-122, we think MS2-consL2(108122) was not immunogenic because the peptide may not have been properly
displayed on the VLPs; previous studies had shown that the isolated peptide
contains neutralizing epitopes [25, 36]. Unfortunately, we could not confirm
genetic display on MS2 due to lack of polyclonal antibodies that include peptide
108-122.
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1.6 Conclusions
In summary, we have shown that inserting a concatemer of two or three L2
peptides on MS2 coat proteins does not affect the ability of the coat proteins to
assemble into VLPs. Additionally, the L2 epitopes are displayed on the VLPs and
immunizations with a mixture of MS2 VLPs displaying multiple L2 epitopes do not
compromise the immunogenicity of each individual epitope on the VLPs. MS2
VLPs displaying the tandem L2 peptide, (20-31) from HPV31 and (17-31) from
HPV16, cross-protected/neutralized selected HR-HPV PsV types, suggesting
that this is an excellent approach to achieve broader protection against more
HPV types.

Moreover, mixing MS2-consL2(108-122)/31L2/16L2 with MS2-

consL2(69-86) VLPs offered protection/neutralization at levels similar to Gardasil9 vaccine, suggesting that these MS2-L2 VLPs are candidates for low valence
yet broadly cross-protective HPV vaccines that should be assessed further for
protection against more HPV types especially those that may be more common
in HIV patients.
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Chapter 2
Oral immunization with bacteriophage MS2-L2 VLPs
protects against oral and genital infection with multiple
HPV types associated with head & neck cancers and
cervical cancer

1.1 Abstract
Human papillomaviruses (HPVs) are the most common sexually transmitted
infections. HPVs are transmitted through anogenital sex or oral sex. Anogenital
transmission/infection is associated with anogenital cancers and genital warts
while oral transmission/infection is associated with head and neck cancers
(HNCs) including recurrent respiratory papillomatosis. Current HPV vaccines
protect against HPV types associated with ~90% of cervical cancers and are
expected to protect against a percentage of HNCs. However, only a few studies
have assessed the efficacy of current vaccines against oral HPV infections. We
had previously developed a mixed MS2-L2 candidate HPV vaccine based on
bacteriophage MS2 virus-like particles (VLPs). The mixed MS2-L2 VLPs
consisted of a mixture of two MS2-L2 VLPs displaying: i) a concatemer of L2
peptide (epitope 20-31) from HPV31 & L2 peptide (epitope 17-31) from HPV16
and ii) a consensus L2 peptide representing epitope 69-86. The mixed MS2-L2
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VLPs neutralized/protected mice against six HPV types associated with ~87% of
cervical cancer. Here, we show that the mixed MS2-L2 VLPs can protect mice
against additional HPV types; at the genital region, the VLPs protect against
HPV53 and at the oral region, the VLPs protect against HPV16, 35, 39, and 58.
Including our colleague’s data (data not shown), mixed MS2-L2 VLPs protect
against eleven oncogenic HPV types

associated with ~95% of cervical

cancer. The VLPs also have the potential to protect, orally, against the same
oncogenic HPVs, associated with ~99% of HNCs. Moreover, mixed MS2-L2
VLPs are thermostable at room temperature for up to 60 days after spray-freeze
drying and they are protective against oral HPV infection.

1.2 Introduction
Human papillomaviruses (HPVs) are non-enveloped DNA viruses with more than
220 different types identified to date [1-3]. Approximately, 40 of these HPV types
are transmitted sexually through anogenital-to-anogenital sex or anogenital-tooral sex [4, 5], and 19 HPV types can cause cancers. Anogenital HPV infections
are associated with cervical cancer, vaginal cancer, penile cancer, anal cancer,
and genital warts [6-10] whereas oral HPV infections are associated with head
and neck cancers (HNCs; oral, oropharyngeal, laryngeal cancers, etc.) including
recurrent respiratory papillomatosis (RRP) [11-15]. Twenty-five percent of HNCs
are caused by HPVs [16]; HPV type 16 is associated with more than 70% of
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HPV-associated HNCs (HPV+HNCs). HPV18 is associated with 14-17% of
HPV+HNCs while the remaining HPV+HNC cases are caused by other
oncogenic HPV types (31, 33, 35, 45, etc.) [11, 17-19]. The prevalence of
HPV+HNC varies from one geographical region to another; 21.1 - 40.8% in
Europe, ~32.4% in Asia, 24.3 - 26.3% in North America, 3.7 - 21.1% in Central &
South American, and 1.0 - 2.5% in Africa [17, 19]. Two prophylactic vaccines
(Gardasil-9 and Cervarix; Gardail-4 has been discontinued) are currently being
used to protect against HPV infections [6, 20, 21]. Amongst these vaccines,
Gardasil-9 offers the broadest level of protection against HPV types (HPV16, 18,
31, 33, 45, 52, 58) that cause ~90% of cervical cancers worldwide and HPV
types (HPV6 and 11) that cause 90% of genital warts/RRP. Despite the
broadness of protection offered by Gardasil-9 vaccine, vaccinated individuals are
still advised to continue cervical cancer screening to make sure they are not
infected with cancer-causing HPV types not included in the vaccine. The HPV
types (e.g. HPV35, 39, 53, 56, etc.) associated with ~10% of cervical cancer not
protected by current vaccines are significantly important especially if this involves
patients infected with human immunodeficiency virus (HIV) or are suffering from
acquired immunodeficiency syndrome (AIDS). Additionally, there is no data on
the efficacy of Gardasil-9 vaccine against oral HPV infections.
To enhance the spectrum of protection and to circumvent these problems,
we developed, in a previous study [22], two bacteriophage MS2 VLPs: i) MS231L2/16L2 VLP displaying a concatemer of HPV31 L2 (amino acid 20-31) &
HPV16 L2 (amino acid 17-31) on its surface; ii) MS2-consL2(69-86) VLP
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displaying a consensus sequence (amino acid 69-86) derived from the alignment
of 19 cancer-causing HPV types and 4 warts-causing HPV types. L2 (the minor
capsid protein) is one of the two capsid proteins of HPV; L2, especially the Nterminus, is highly conserved among HPV types and is a target for nextgeneration HPV vaccines [23-26]. In Zhai et al. 2017, we showed that mice
immunized, intramuscularly, with a mixture of the VLPs, MS2-31L2/16L2 and
MS2-consL2(69-86), elicited high-titer (>104) IgG antibodies and protected the
mice from vaginal challenge with HPV pseudoviruses representing HPV16, 18,
31, 45, and HPV33 at levels similar to Gardasil-9; suboptimal protection was
observed against HPV58 [22]; these six HPV types are associated with ~87% of
cervical cancer and ~90% of HPV+HNCs. To build on that study, we assessed
whether oral immunization with the mixed MS2-L2 VLPs in the presence of two
mucosal adjuvants (cholera toxin and monophosphoryl lipid A) can protect mice
from oral and/or vaginal infection with additional HPV pseudovirus types (HPV35,
39, 52, and 53) associated with ~8.9% of HPV+HNC and ~8.0% of cervical
cancer; oral immunization (including other mucosal approaches) with cholera
toxin or monophosphoryl lipid A has been shown to elicit protective mucosal and
systemic immune responses [27-30].

We also assessed whether the mixed

VLPs can be developed into a heat-stable dry powder formulation with mucosal
adjuvants; we assessed the thermostability/immunogenicity of the dry powder
VLPs stored at room temperature for 60 days.
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1.3 Materials and Methods
1.3.1 Production of MS2-L2 VLPs
Plasmids encoding recombinant MS2-L2 proteins -- MS2 coat protein with an
insertion of a concatemer of HPV L2 epitope containing amino acids (aa) 20-31
from HPV31 L2 and aa 17-31 from HPV16 L2 (MS2-31L2/16L2) or MS2 coat
protein with an insertion of a consensus HPV L2 epitope [MS2-consL2(69-86)] were previously described [22]. The plasmids were used to transform C41
Escherichia coli (E. coli) cells. Protein expression and VLPs purification were
conducted as previously described [22]. Briefly, transformed bacterial C41 culture
was induced with 0.5 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) for 3
hours and the bacteria were lysed with 0.2% lysozyme solution [for MS2consL2(69-86) VLPs] or 10 mM Borax (for MS2-31L2/16L2 VLPs). Soluble VLPs
were precipitated with 50% ammonium sulfate and purified using sepharose
cross-linked CL-4B columns.

1.3.2 Spray-freeze drying of VLPs into dry powder formulation
Equal concentrations of MS2-31L2/16L2 VLPs and MS2-consL2(69-86) VLPs
were mixed together to obtain mixed MS2-L2 VLPs. Half of the mixed MS2-L2
VLPs (100 µg) was further mixed with 2 µg each of the mucosal adjuvants,
cholera toxin (CT) and monophosphoryl lipid A (MPLA); control MS2 VLPs were
mixed with the same concentration of adjuvants. The mixed MS2-L2 VLPs and
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MS2 VLPs, with or without mucosal adjuvants, were added to a 3% w/v MTDL
excipient solution (containing Mannitol (M, 75% w/w), Trehalose (T, 7.5% w/w),
Dextran (D, 2.5% w/w), and L-Leucine (L, 15% w/w). The VLPs were added at a
concentration of 8% w/w to the MTDL excipients and the VLPs-excipients were
then spray-freeze dried (SFD) in two steps using a method adapted from Tonnis
et al., 2014 and Ali et al., 2014 [31, 32]. In the first step, the VLPs-excipients
suspensions were sprayed into a stainless-steel container filled partially with
liquid nitrogen. This was achieved by using a two-fluid nozzle (0.7 mm) which is
part of a Büchi B-290 mini spray-dryer; the spraying operating conditions were as
following: nitrogen flow (Q) between 10 and 15mm, and a VLPs-excipients feed
rate of ~ 4 mL/min. Subsequently, the liquid nitrogen in the steel container was
allowed to evaporate and the frozen droplets were transferred into a lyophilizer
(FreeZone® Triad™ Freeze Dry system, Model 74000 Series) [31] for freezedrying (the second step). Freeze-drying was conducted under the following
conditions: pre-freeze for 3 h at -80 °C, primary drying at -10 °C for 24 h with a
ramp of 0.25 °C/min, followed by secondary drying at 15 °C for 48 h with a ramp
of 0.25 °C/min, and vacuum pressure of 1.51 mBar. All SFD products were
collected in glass scintillation vials and were stored under refrigeration until
further use.

57

1.3.3 Assessing the thermostability of SFD VLPs
Spray-freeze dried VLP powders were loaded into capsules, transferred to
amber-colored Wheaton glass bottles and sealed with 20 mm butyl septa caps.
The bottles were then purged with nitrogen gas and crimped with tear-away
aluminum seals using a vial seal crimper [33]. The sealed bottles were then
stored at 4 oC or room temperature for 60 days. The powders were then
reconstituted in 1X phosphate buffered saline (PBS) and the integrity of VLPs
was assessed, in comparison to non-spray-freeze dried VLPs, by transmission
electron microscopy (TEM; 30,000X magnification). The immunogenicity of the
reconstituted VLPs was assessed by immunizing mice as described below.

1.3.4 Immunization of mice and assessing antibody responses
All animal work was conducted following Michigan Technological University
Institutional Animal Care and Use Committee (IACUC) guidelines (Protocol
number L0264). Groups of female balb/c mice (4-6 mice per group) were
immunized thrice orally, by placing VLPs underneath the tongue or by injecting
into the buccal region, at two-week intervals with freshly prepared (non-sprayfreeze dried) mixed MS2-L2 VLPs [50 µg each of MS2-31L2/16L2 VLPs and
MS2-consL2(69-86)] mixed with either 2 µg of CT, 2 µg of MPLA, a combination
of the two adjuvants (same concentrations), or without adjuvants. Other groups
of mice were immunized with control MS2 VLPs and same adjuvant
combinations for comparison. In all immunizations, 5 µg of Gardasil-9 was used
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as controls administered intramuscularly because it does not contain mucosal
adjuvants.
To assess the immunogenicity of the spray-freeze dried VLPs, 100 µg of
the reconstituted SFD mixed MS2-L2 or SFD control MS2 VLPs (all SFD with CT
and MPLA adjuvants) were used to immunize mice as described above (same
route and schedule). Other groups of mice were immunized with the same
concentration of reconstituted SFD VLPs but with additional 2 µg each of fresh
liquid CT and MPLA adjuvants; the latter will assess whether the activity of the
adjuvants were inactivated during the SFD process. The VLPs that were SFD
without the adjuvants were immunized (at same concentration) with 2 µg each of
fresh liquid CT and MPLA adjuvants.
In all immunizations, sera and saliva were collected two weeks after the
last immunizations. IgG antibody titers in sera were conducted by peptide-ELISA
as previously described [34]. Briefly, 96-well plates were coated, overnight, with
500 ng HPV16 L2 peptide conjugated to streptavidin. The plates were blocked for
two hours with 0.5 % non-fat milk in 1X PBS. The plates were incubated with 4fold serial dilutions of serum for two hours. Horseradish peroxidase (HRP)conjugated goat anti-mouse IgG (1:5000 dilution) antibodies were added to the
plates for one hour. The wells were washed and developed with 3, 3', 5, 5'Tetramethylbenzidine (TMB) and stopped with 1M hydrogen chloride solution.
Antibody titers were determined (at optical density 450) as the reciprocal of
highest sera dilutions at which reactivity of experimental sera was at least twice
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that of control sera. IgA antibody titers in saliva were determined also by peptideELISA with 100 µL saliva samples as primary antibodies. HRP-conjugated goat
anti-mouse IgA (1:500) antibodies were added for one hour and the plates were
developed as described above except without the stop solution. IgA antibodies
were determined by comparing the optical density (405 nm) values of
experimental group to those of control group.

1.3.5 Oral and vaginal infection with HPV pseudoviruses (PsVs)
HPVs pseudoviruses representing PsVs 16, 35, 39, 53, and 58 were expressed
and purified by cesium chloride gradient ultracentrifugation as previously
described [26]. The PsVs encode a reporter plasmid that expresses green
fluorescence protein and luciferase. For vaginal infection, immunized mice were
treated with Depo-provera and PsVs (16 and 53) infection was conducted as
previously described [22]. For oral infection, immunized mice were injected at the
buccal region with PsVs (16, 35, 39 and 58); 1 - 7 x 106 infectious unit (IU) of
PsVs were used in all infections. Forty-eight hours post-infection, mice that were
infected orally were injected in the buccal region with 1 mg of luciferin, while
those that were infected vaginally were instilled vaginally with 0.4 mg of luciferin.
In both cases, the mice were imaged using IVIS Spectrum at one-minute
exposure. Average radiance (p/s/cm2/sr) was determined by drawing equally
sized regions of interests surrounding the site of PsV instillation.
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1.3.6 Statistical analysis
Statistical analyses for ELISAs and of HPV PsV challenge studies were done
using unpaired two-tailed t-test and unpaired one-tailed t-test, respectively.

1.4 Results
1.4.1 Buccal immunization with mixed MS2-L2 VLPs plus mucosal
adjuvants elicits protective immune responses at the vaginal and oral
regions
To assess which delivery method of oral immunization will elicit immune
responses, mice were immunized by placing freshly prepared (non-spray-freeze
dried) mixed MS2-L2 VLPs with/without cholera toxin and MPLA in the floor of
the mouth or by injecting the buccal area of the mouth with the VLPs. We then
assessed IgG and IgA antibody levels in sera and saliva, respectively. Mice
immunized by injecting the floor of the mouth with the VLPs elicited high-titer IgG
antibodies in the sera (Fig. 1A) but no detectable IgA in saliva (data not shown).
Mice immunized with the mixed MS2-L2 VLPs in the presence of the two
adjuvant combinations (mixed MS2-L2 VLPs + CT/MPLA) elicited higher IgG
titers (p<0.0001) compared to mice immunized with the same VLPs but with only
one of the adjuvants (especially mixed MS2-L2 VLPs + MPLA; p=0.0140). Mice
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immunized by placing the VLPs in the floor of the mouth did not elicit immune
response in the sera or in the saliva (data not shown). Thus, all subsequent
immunization studies were conducted by injecting the buccal region of the mouth
and with the two-adjuvant combinations (CT/MPLA).
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Fig. 1. Immunogenicity of mixed MS2-L2 VLPs with/without mucosal
adjuvants (CT or MPLA) and protection from PsV16 and 53. Mice were
immunized (buccal injection) thrice with 100 µg of mixed MS2-L2 VLPs or control
MS2 VLPs with/without CT, MPLA or with/out the two-adjuvant combinations at
two-week intervals. Sera were collected two weeks after the last immunization.
A) Anti-L2 peptide IgG titers in sera were determined by end-point dilution ELISA
using 16L2 (17-31) peptide as the target peptide. Each datum represents
antibody titer in each mouse and the black horizontal lines represent geometric
mean for each group. B) The mice in (A) were vaginally challenged with ~3 x 106
IU of HPV PsV16. C) Additional groups of mice were immunized by buccal
injection with 100 µg of mixed MS2-L2 VLPs, control MS2 VLPs, and 5 µg of
Gardasil-9 vaccine (immunized intramuscularly). The mice were vaginally
challenged with 1.6 x 106 IU of PsV 53. The average radiance (p/s/cm2/sr) of
luciferase expression was determined using Living Image 4.5.5 software. Each
datum represents the average radiance of an individual mouse and the lines
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represent the geometric mean for each group. The P-values for ELISAs and
infection assays were determined by unpaired two-tailed t-test and unpaired onetailed t-test, respectively.

To assess if the immune responses elicited by buccal immunization were
protective, we challenged the mice vaginally, using a well-characterized method
for HPV infection [34, 35]. As shown in Fig. 1B, mice immunized with mixed MS2L2 VLPs with CT/MPLA showed better levels of protection (p<0.0001) from HPV
PsV16 infection compared to mice immunized with only one of the two adjuvants
(especially those immunized with MPLA; p=0.0072). To test if buccal
immunization with mixed MS2-L2 VLPs offered cross-protection against other
HPV PsVs, vaccinated mice were vaginally infected with high-risk HPV PsV53,
which is not included in Gardasil-9 vaccine. Mice immunized with mixed MS2-L2
VLPs offered complete protection against PsV53 while Gargasil-9 offered no
protection against PsV53 (Fig. 1C).
Having demonstrated that buccal immunization protected mice from vaginal
infection by HPV PsVs 16 and 53, we decided to assess if buccal immunization
can protect mice from oral infection with PsV16 and other PsVs (35, 39 and 58).
In Fig. 2, buccal immunization with mixed MS2-L2 VLPs + CT/MPLA protected
mice from oral infection with PsVs 16, 35, 39 and 58. While mixed MS2-L2 VLPs
and Gardasil-9 (immunized intramuscularly) offered similar levels of protection
against PsV16, Gardasil-9 offered better protection against PsV58 and mixed
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MS2-L2 VLPs offered best protection against PsV35 and PsV39 (Fig. 2B).
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Fig. 2. Buccal immunization with mixed MS2-L2 VLPs and oral protection
from HPV PsVs 16, 35, 39 and 58. Mice immunized (buccal injection) thrice (at
two-week intervals) with 100 µg of mixed MS2-L2 VLPs, control MS2 VLPs, and
5 µg of Gardasil-9 vaccine (immunized intramuscularly) were orally challenged
with: A) 7 x 106 IU of PsV16 and B) 1 - 7 x 106 IU of PsVs 35, 39 and 58. Each
datum represents the average radiance of an individual mouse and the lines
represent the geometric mean for each group. The P-values were determined by
unpaired one-tailed t-test.
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1.4.2 Mixed MS2-L2 VLPs can be SFD without a mixture of cholera
toxin/MPLA adjuvants
To assess if mixed MS2-L2 VLPs can be SFD into a product that is thermostable
at room temperature, the VLPs with or without CT/MPLA were SFD with
stabilizing excipients and the integrity of the VLPs was assessed by TEM. As a
control, MS2 VLPs with same adjuvants and excipients were also SFD. While
mixed MS2-L2 VLPs or MS2 VLPs in the absence of adjuvants were successfully
SFD (based on the integrity of the VLPs after reconstitution of the powder in PBS
buffer in comparison to non-SFD VLPs), the VLPs could not be SFD with the
adjuvants (Fig. 3). SFD with adjuvants caused the VLPs to agglomerate (Fig.
3A).
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Fig. 3. Transmission electron microscopy (TEM) images of spray-freeze
dried (SFD) VLPs and non-spray-freeze dried VLPs. Mixed MS2-L2 VLPs and
MS2 control VLPs were SFD with/without mucosal adjuvants (CT and MPLA) and
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the dry powders were reconstituted in PBS and analyzed (in comparison with
fresh liquid VLPs) using a TEM. A) TEM of spray-freeze dried VLPs with
CT/MPLA, B) TEM of spray-freeze dried VLPs without CT/MPLA, and C) TEM of
fresh liquid VLPs. Images were taken under 30,000X magnification.

To assess whether the SFD VLPs (those that did not agglomerate and those that
agglomerated) were still immunogenic, we immunized mice (in buccal region)
with the VLPs with/without additional CT/MPLA adjuvants. Mixed MS2-L2 VLPs
SFD without adjuvant, but adjuvant combinations were added (+ CT/MPLA) just
prior to immunization were highly immunogenic compared to the VLPs [mixed
MS2-L2 VLPs (CT/MPLA)] that were SFD together with the adjuvant
combinations (Fig. 4A). The addition of more adjuvant (+ CT/MPLA) to the latter
[mixed MS2-L2 VLPs (CT/MPLA)] slightly enhanced the immunogenicity of the
VLPs but this was not significant. The mice immunized with mixed MS2-L2 VLPs
+ CT/MPLA were significantly protected from vaginal infection with HPV PsV16
while mice immunized with mixed MS2-L2 VLPs (CT/MPLA) + CT/MPLA elicited
suboptimal protection against PsV16 infection (Fig. 4B). Also, the group of mice
(SFD mixed MS2-L2 VLPs + CT/MPLA-immunized; Fig. 4B) that showed
complete protection from vaginal infection with PsV16 was completely protected
from oral infection with the same PsV type (Fig. 4C).

70

71

Fig. 4. Buccal immunization with reconstituted SFD mixed MS2-L2 VLPs,
vaginal and oral protection from HPV PsV16. Spray-freeze dried VLPs were
reconstituted in PBS and mice were immunized thrice with SFD VLPs with/out
addition of fresh CT/MPLA adjuvants. A) Sera were collected two weeks after the
last immunization and anti-L2 peptide IgG titers in sera were determined by endpoint dilution ELISA using 16L2 (17-31) peptide. Each datum represents antibody
titer in each mouse and the black horizontal lines represent geometric mean for
each group. B) The mice in (A) were vaginally challenged with ~3 x 106 IU of
HPV PsV16. C) Mice immunized (buccal injection) with reconstituted SFD mixed
MS2-L2 VLPs or control MS2 VLPs (in the presence of fresh CT/MPLA
adjuvants) were orally challenged with ~7 x 106 IU of PsV16. Each datum
represents average radiance of an individual mouse and the lines represent the
geometric mean for each group. The P-values for ELISAs and infection assays
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were determined by unpaired two-tailed t-test and unpaired one-tailed t-test,
respectively.

1.4.3 SFD mixed VLPs are thermostable at room temperature for up to 60
days and elicit protective responses
To evaluate if spray-freeze dried VLPs are thermostable, the VLPs (SFD without
adjuvants; Fig. 5A) were stored at room temperature and 4°C for 60 days and
their integrities were assessed using TEM. As shown in Figs. 5B and 5C, SFD
VLPs stored at either temperature did not disintegrate during storage; their
integrities look similar to freshly prepared non-SFD VLPs (Fig. 5D). Moreover,
buccal immunization with the SFD mixed MS2-L2 VLPs (stored at room
temperature for 60 days) protected mice from oral infection with HPV PsV16 (Fig.
6).
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Fig. 5. TEM images of SFD VLPs after two months storage. Mixed MS2-L2
VLPs and MS2 control VLPs spray-freeze dried without adjuvants were loaded
into capsules, sealed in amber-colored Wheaton glass bottles, and purged with
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nitrogen gas (A). The vials with the VLPs were stored at room temperature or 4
°C for 60 days. After 60 days, the spray-freeze dried VLPs were removed from
the capsules, reconstituted in PBS buffer. TEM was done and images of the
VLPs stored at: B) room temperature and C) 4 °C taken. The VLPs were
compared to non-SFD VLPs (D). Images were taken at 30,000X magnification.

Fig. 6. Buccal immunization with reconstituted SFD mixed MS2-L2 VLPs
after 60-day storage and oral protection from HPV PsV16. Spray-freeze dried
VLPs were reconstituted in PBS after 60-day storage at room temperature. The
reconstituted VLPs in the presence of fresh CT/MPLA adjuvants were used to
immunize mice thrice. Immunized mice were orally challenged with 7 x 106 IU of
HPV PsV16. Each datum represents the average radiance of an individual
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mouse and the lines represent the geometric mean for each group. The P-values
were determined by unpaired one-tailed t-test.

1.5 Discussion
HPV-associated HNCs are on the rise especially oropharyngeal squamous cell
carcinomas (OPSCC), a type of HPV+HNC. The number of HPV-associated
OPSSCs has increased by more than 225% within the last half of the century due
to an increase in the number of people engaged in oral sex (a route of
transmission) [11, 13, 36, 37]. It has been suggested that if the trend continues,
the number of HPV+OPSCCs will surpass those of cervical cancer cases in the
United States [13]. While there are validated methods (Pap smears) to screen for
cervical cancer, there are no validated methods to screen for HNCs, thus making
early preventive interventions for HNCs very challenging. Preventive measures
therefore have to rely on preventing HPV infection of the head and neck region
during oral sex.
Two prophylactic vaccines (Gardasil-9 and Cervarix; Gardasil-4 is
discontinued) are currently approved to protect against HPV infection. Gardasil-4,
which protected against HPV6, HPV11, HPV16 and HPV18 has been shown to
elicit oral IgG antibodies [38, 39], oral antibodies neutralize/protect against HPV6,
HPV16, HPV18 [40, 41], and reduce oral prevalence of vaccine types (HPV types
included in the vaccine) in vaccinees [42-44]. However, a protective effect of the
76

vaccine on HPV types not included in the vaccine was not observed. The
second-generation HPV vaccine, Gardasil-9, has VLPs from seven oncogenic
HPV types (HPV16, 18, 31, 33, 45, 52, 58) and two non-oncogenic HPV types
(HPV6, 11) included in the vaccine [6, 45, 46]. Although no studies have
assessed the efficacy of the vaccine against oral HPV infection, like Gardasil-4, it
is anticipated that the vaccine will offer oral protection against HPV types
included in the vaccine; Gardasil-9 is therefore expected to protect against ~93%
HPV+HNCs and >90% recurrent respiratory papillomatosis, respectively, based
on the implication of each HPV type in HNCs [6, 16, 18]. As an alternative to
Gardasil-9, we developed a bacteriophage-based MS2-L2 VLP candidate
vaccine against HPVs [22]. Mixed MS2-L2 VLPs [a mixture of MS2-31L2/16L2
and MS2-consL2(69-86)] neutralized and offered vaginal protection against six
oncogenic HPV pseudovirus types (HPV16, 18, 31, 33, 45 and HPV58
associated with ~87% of cervical cancer) following intramuscular immunization. It
has been reported that mucosal vaccines compared to injectable vaccines
provide additional secretory antibody protection against pathogens at mucosal
site [47]. Here, we assessed the immunogenicity of mixed MS2-L2 VLPs
following oral immunization in the presence of two mucosal adjuvant
combinations, cholera toxin and MPLA, that target different immune response
pathways. Cholera toxin is a mucosal adjuvant that binds to ganglioside
receptors (on all cells including epithelial cells, dendritic cells, macrophages, Band T-lymphocytes) [48-50] and activates the mitogen activated protein kinase
(MAPK) signal transduction pathway thus activating the immune system. MPLA,
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an approved vaccine adjuvant, binds to toll-like receptors (TLR4 on B cells,
dendritic cells, and macrophages) and activates the MyD88 signaling pathway,
which also activates the immune system [48, 49]. Our results show that buccal
immunization of mixed MS2-L2 VLPs without adjuvant offers only suboptimal
protection from vaginal infection (Fig. 1B). However, in the presence of one of the
two mucosal adjuvants (cholera toxin and MPLA), the protection level was
enhanced; moreover, robust protection was observed when the two-adjuvant
combinations were used in immunization (Figs. 1B & 1C); these results are
consistent with previous studies, which showed that the immunogenicity of an
antigen, as well as the longevity of response, can be enhanced by immunizing
with more than one adjuvant combination [51-55]. These results suggest that
targeting different immune signaling pathways, simultaneously, is a better
strategy to enhance mucosal immune responses at the genital and the oral
regions. This was further demonstrated by the level of protection observed at the
oral region. Mixed MS2-L2 VLPs protected against five HPV types (HPV16, 35,
39, 58) associated with ~80% of HNCs (Figs. 2A and 2B). The protection levels
against HPV PsVs 35 & 39 were superior to that offered by Gardasil-9 vaccine
(which does not include HPV35 & 39 virus-like particles). To the best of our
knowledge, this is the first study that has assessed oral protection using diverse
HPV pseudovirus types and has assessed, simultaneously, protection at the oral
& the genital regions in the same mice. For example, the groups of mice infected
orally with PsV35 (Fig. 2B) were simultaneously infected vaginally with PsV56
(Fig. 1C).
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In a previous study, we observed that an MS2 VLP, MS2-16L2, with an HPV L2
insertion (amino acid 17-31 from HPV16) disintegrated when stored at room
temperature for 1 month [56]; this made the MS2-16L2 VLPs less suitable for
developing countries with poorly developed refrigeration & temperaturemonitoring infrastructures for transportation and storage of vaccines. To this end,
we assessed the potential of formulating mixed MS2-L2 VLPs together with
cholera toxin and MPLA into a dry powder, with the ultimate goal of enhancing its
thermostability of the candidate vaccine. We SFD the VLPs together with the
adjuvants. However, the VLPs agglomerated when SFD with the adjuvants and
were not immunogenic even with the addition of more adjuvant prior to
immunization (Fig. 4A). Given this setback, we tried another technique, spray
drying, to formulate the VLPs into dry powder; however, similar results
(agglomeration) were obtained (data not shown). These results are consistent
with other studies, which showed that spray drying of vaccines with adjuvant
(alum) lead to vaccine agglomeration [57]. Taken together, these results suggest
that certain antigens may not be amenable to SFD or spray drying with
adjuvants. Irrespective of this, the mixed MS2-L2 VLPs were successfully SFD
into dry powder without the adjuvants and could be stored at room temperature,
without the VLPs disintegrating, for up to 60 days (Figs. 3 and 5). Moreover, the
SFD VLPs offered robust protection from oral HPV infection.
In summary, the display of a concatemer of epitope 17-31 from HPV16L2 &
epitope 20-31 from HPV31 on one VLP and the display of consensus epitope 69-
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86 on another VLP [22] is an excellent approach to elicit broad protection against
diverse HPV types. Mixed MS2-L2 VLPs [MS2-31L2/16L2 VLPs and MS2consL2(69-86)] is a candidate HPV vaccine with the potential to offer protection
against multiple HPV types at the oral and genital regions. In a previous study
[22], we showed that the candidate vaccine offers protection from genital
infection against six oncogenic HPV types (HPV16 18, 31, 33, 45, and 58). Our
colleague has also shown that the candidate vaccine prevents oral infection from
HPV 52 and genital infection from HPV 56 and HPV11 (data not shown). In the
current study, we show that the candidate vaccine offers protection from genital
with HPV PsVs 53 and protection from oral infection with HPV PsVs 16, 35, 39,
58. Although we did not assess, in the current study, protection from oral
infection with HPV PsVs 18, 31, 33, 45, 53, 56 and PsV11, we expect immunized
mice to offer oral protection against these viruses given the level of protection
that was observed at the vaginal region with these PsVs in our previous [22].
This view is supported by the fact that mice immunized with the mixed MS2-L2
VLPs, in our previous study [22], protected the mice from vaginal infection with
HPV PsV16 (at levels similar to Gardasil-9) and similar levels of protection
against PsV16 were observed at the oral region in the current study. Overall,
mixed MS2-L2 VLPs has the potential to orally protect against eleven oncogenic
HPV types (16, 18, 31, 33, 35, 39, 45, 52, 53, 56, and 58) associated with ~99%
of HNCs (estimates are based on the contribution of each HPV type to HNCs
[16-19]). The candidate vaccine also has the potential to protect, genitally,
against the same eleven oncogenic HPV types associated with ~95% of cervical
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cancer (estimates are based on the contribution of each HPV type to cervical
cancer [6, 58]). The candidate vaccine also shows protection against HPV11
associated with 19-32% of recurrent respiratory papillomatosis [59, 60] and 36%
of genital warts [61, 62]. Thus, mixed MS2-L2 VLPs is a next generation HPV
vaccine that should be evaluated further, especially for patients infected with HIV
or are suffering from AIDS. HPV type distribution in HIV patients seems to be
different from the normal population [6]; in addition to the other HPV types (16,
18, 31, 33, 45, 52, 58) that are common in the normal population, HIV patients
are infected or co-infected mostly with HPV35, 39, 53, 56, which are all protected
by mixed MS2-L2 VLPs.
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Chapter 3
Novel Expression of Coat Proteins from Thermophilic
Bacteriophage ΦIN93 and Evaluation for Assembly into
Virus-like Particles
1.1 Abstract
The structural proteins of viruses can spontaneously assemble to form virus-like
particles (VLPs) without the viral genome. VLPs are empty viral shells without the
whole viral genome and not infectious. Overexpression of viral coat or envelope
proteins in a suitable host cell allows the proteins to self-assemble into VLPs.
VLP vaccines such as human papillomaviruses (HPVs) and hepatitis B virus
(HBV), have been approved to protect against HPVs and HBV infections,
respectively. In addition to this, a large group of researchers are working on
adopting VLPs as a display platform to develop chimeric VLPs vaccines
displaying heterologous antigens from other viruses, bacteria, parasites and even
tumor-associated antigens. However, there are some challenges/limitations using
current VLP display platform. For example, there are limitations on the size of a
heterologous peptide that can be displayed on a VLP, the VLP not thermostable
at room temperature, and pre-existing antibody to the VLP platforms my limit
their use to elicit antibodies against heterologous antigens. To address some of
these questions, especially thermostability and pre-existing antibodies, we
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decided to explore if two coat proteins, open reading frame (ORF) 13 and
ORF14, from a thermophilic bacteriophage, ΦIN93, can be expressed in E. coli
and if the coat proteins can assemble into VLPs. Here, we co-expressed and
purified ORF13 and ORF14 proteins from E. coli. Our results seem to suggest
that co-expression of two truncated versions of the coat proteins have potential to
form structures that resemble VLPs. To the best of our knowledge, this is the first
attempt to develop a new thermophilic VLP platform based on s thermophilic
bacteriophage.

1.2 Introduction
Viral genomes code for structural and non-structural proteins. Non-structural
proteins include enzymes required for viral replication while structural proteins
are protein components assembled around the viral genome to form a virus
particle (virion) and include capsid (coat) proteins and in some cases envelope
proteins [1]. The structural proteins by themselves can also assemble, naturally
during the life cycle of a virion, without the viral genome to form structures,
known as virus-like particles (VLPs) (reviewed in [2]). VLPs are therefore empty
viral shells without the viral genome. VLPs can be generated by cloning and
expression of the coat protein(s) or envelope proteins in a suitable host cell.
Overexpression of coat proteins or envelope proteins in a host cell allows the
proteins to spontaneously self-assemble into VLPs [3, 4].
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VLPs can be derived from animal viruses, plant viruses, human viruses, and
even from bacterial viruses (bacteriophages). VLPs have so many applications in
science and in medicine; they can be used in pre-clinical studies to deliver
drugs/cargo to specific cancer cells, to develop armored RNA (positive controls
for diagnostic tests for infectious diseases), and for in vivo imaging (VLPs loaded
with fluorophores). Furthermore, because VLPs resemble viruses in terms of
size, multivalency of coat proteins on capid, inability to replicate, and in terms of
immunogenicity, they have can also be used to develop vaccines [5-9]. Two
VLPs-based vaccines, derived from human papillomaviruses (HPVs) and
hepatitis B virus (HBV), have been approved by the Food and Drug
Administration (FDA) to protect against HPVs [10, 11] and HBV [2] infections,
respectively; other VLPs-based vaccines against viruses are under development
or in clinical trials [12, 13].

VLPs cannot only be used to develop vaccines

against viruses from which the structural proteins are derived from but they can
also be used as display platforms to develop chimeric VLPs vaccines displaying
heterologous antigens from other viruses [14-18], bacteria [19], parasites [20, 21]
and even tumor-associated antigens [22]. The goal of chimeric VLPs is to elicit
immune response against the heterologous antigens on the platform. Thus, VLPs
have been applied to develop candidate vaccines against both microbial and
non-microbial diseases [23] ranging from allergy, hypotension, cholesterol [24], to
cancer [22].
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Despite the success of using VLPs as platforms to develop candidate
vaccines, there are some challenges associated with current VLPs platforms.
Some coat proteins have limitations on the size and the type of heterologous
antigens that can be genetically inserted on the coat proteins without affecting
the ability of the coat proteins to assemble into VLPs [5, 25, 26]. Additionally,
some VLPs are not thermostable; in some cases, thermostability decreases with
the insertion of heterologous antigens [27, 28]. Furthermore, most VLPs
platforms used for peptide display (chimeric VLPs) including vector platforms, for
vaccine design, are derived from viruses that infect humans and/or humans had
previously been immunized with VLPs or antigens derived from these viruses.
Thus, pre-existing antibodies against the VLPs display platforms in the general
population, may compromise the immunogenicity of the display platforms and
ultimately that of heterologous antigens displayed on the platforms. [29, 30]. To
address some of these challenges, we assessed whether the coat proteins from
a bacteriophage, ΦIN93, can assemble into VLPs. Bacteriophage ΦIN93 is a
thermophilic virus isolated from a thermophilic bacterium, Thermus aquaticus
with optimum growth temperature of 75°C [31].
Bacteriophage ΦIN93 is a double-stranded DNA virus with a circular
genome size of ~19.4kbp. Two putative coat proteins, open reading frame (ORF)
13 and ORF14, have been identified in the bacteriophage based on sequence
homology with the major coat proteins (VP16 and VP17) of another thermophilic
bacteriophage, P23-77 [32]. ORF13 and ORF14 of thermophilic bacteriophage
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ΦIN93 are 80% and 73% identical, respectively, to VP16 and VP17 of P23-77
(Fig. 1). It has been shown that a mixture of VP16, VP17, and VP11 (a minor
capsid protein) of P23-77 can form complexes in vitro [33], which is a prelude to
assembly/VLPs formation. However, no studies have ever assessed the
expression of ORF13 and ORF14 from bacteriophage ΦIN93 or assessed the
ability of these coat proteins to assemble into VLPs. Here, we assessed for the
first time, the expression of ORF13 and ORF14 in a bacterial expression system
and assessed the potentials of the coat proteins to assemble into VLPs with the
long-term goal of developing a novel thermophilic bacteriophage VLPs platform
for vaccine design.
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Fig. 1. Sequence alignments of coat proteins of bacteriophages ΦIN93 and
P23-77. Sequence alignment of: A) ORF13 of bacteriophage ΦIN93 & VP16 of
bacteriophage P23-77 and B) ORF14 of bacteriophage ΦIN93 & VP17 of
bacteriophage P23-77. Alignments were done using Clustal Omega. Asterisk (*)
denotes identical amino acids, colon (:) denotes amino acids with similar
properties and period (.) denotes amino acids with weak similar properties.
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Amino acids highlighted in gray-background were used in model structures in
Figure 4.

1.3 Materials and methods
1.3.1 Generation of expression vectors
The genes encoding potential coat proteins (ORF13 and ORF14) of
bacteriophage ΦIN93 were codon-optimized for high-level protein expression in
E coli bacteria and were synthesized by Epoch Life Science. The complete
sequence of each gene was separately amplified by polymerase chain reaction
(PCR) and cloned into pET28a plasmid (Kanamycin resistance) and pET15b
plasmid (Ampicillin resistance) using NcoI and BamHI restricted sites; this gave
rise to four plasmids, namely: pET15b-ORF14, pET28a-ORF13, pET15b-ORF13,
and pET28a-ORF14.
In addition to cloning the complete sequences of ORF13 and OFR14, we
also generated truncated versions of each of the two genes. To generate
truncated ORF13 and ORF14 genes, DNA sequences representing amino acids
(aa) 21-165 and aa 46-271, respectively, were separately amplified by PCR and
each truncated gene was cloned into the pET28a and pET15b using the same
restriction sites above; this gave rise to four additional plasmids, namely:
pET15b-ORF13-trunc with aa 21-165, and pET15b-ORF14-trunc with aa 46-271,
93

pET28a-ORF13-trunc with aa 21-165, and pET28a-ORF14-trunc with aa 46-271.
In all cases, the genes in each of the constructs were sequenced across
restriction sites to confirm the cloning.

1.3.2 Coat protein expression and purification
For coat protein expression, C41 E. coli cells were transformed separately with
each plasmid and single colonies were screened for protein expression as
follows. Bacterial cultures from colonies were grown in Luria-Bertani (LB)
medium at 37 oC until the culture reached an optical density (OD)600 of 0.6. Coat
protein

expression

was

induced

with

0.5

mM

Isopropyl

β-D-1-

thiogalactopyranoside (IPTG) overnight at the same temperature. For coexpression of ORF13 and ORF14 in the same bacteria, equal concentrations of
pET15b-ORF14 and pET28a-ORF13 or pET28a-ORF14 and pET15b-ORF13 or
pET28a-ORF13-trunc and pET15b-ORF14-trunc or pET15b-ORF13-trunc and
pET28a-ORF14-trunc were mixed and used to transform C41 cells. Transformed
cells were grown in LB medium with 30 µg/ml of kanamycin plus 50 µg/ml of
ampicillin at the same temperature until the culture reached an OD600 of 0.6. Coat
protein expression was induced with 1 mM IPTG under the same conditions and
time as above. To screen for coat protein expression, bacterial cells were
pelleted, resuspended in 8M urea, sonicated and resolved on SDS-PAGE gel.
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Cultures, which showed protein expression, were used to grow large volume
cultures (100 ml or 250 ml) for large-scale protein expression and purification.
The cultures were grown and induced as above. Cell pellets were then lysed
using 0.2% lysozyme solution (100 mM NaCl, 10 mM EDTA, 50 mM Tris-HCl PH
8.5 plus 0.05% deoxycholate) and sonicated to help lyse the bacteria. Two ng/ul
of DNase and 2 mM of MgCl2 were added to the lysates and the lysates were
incubated for 1 hour at 37 oC. Lysates were spun at 3,700 rpm (4 oC) for 30
minutes and the supernatants collected and resuspended in 50% ammonium
sulfate to precipitate coat proteins. The supernatants with precipitated coat
proteins were spun at 10,000 rpm (4 °C) for 10 minutes. The pellets were
resuspended in sepharose column buffer (SCB: 10 mM Tris-HCl PH 7.4, 100 mM
NaCl, 0.1 mM MgSO4), spun at the same time and conditions. Supernatants were
then loaded on sepharose cross-linked CL-4B column and factions were
collected. Fractionation tubes containing coat proteins were combined and the
SCB buffer was exchange with PBS (1x phosphate buffered saline) using
Millipore Amicon™ Ultra-4 Centrifugal Filter Units (100K MWCO).

1.3.3 Generation of bacteriophage ΦIN93
ΦIN93 was amplified and purified as previously described [31]. Briefly, 100 ul of
overnight culture (70 °C) of Thermus thermophilus bacterial strain TZ2 was used
to inoculate a fresh A2 medium (0.1% tryptone, 0.1% yeast extract, and
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Castenholtz basal salts pH 7.5). The culture was grown at 70 °C for 4 hours and
was subsequently inoculated with a plaque of bacteriophage ΦIN93. Then, the
culture was shaking for another 2.5-3 hours until the media became clear (Lysis).
The culture was spun down at 3000 rpm for 10 min and the supernatant which
contained phage was saved.

1.3.4 Transmission electron microscopy (TEM)
To assess the potential of coat proteins to assemble into VLPs, TEM was
conducted as follows. Purified coat proteins of bacteriophage ΦIN93 or the virus
were loaded onto glow-discharged carbon grids for 2 minutes and then grids
were stained with 2% uranyl acetate for 2 minutes. Samples were visualized at a
magnification of 10,000 X.

1.3.5 Generation of sera for immunoassays
To generate sera that can react with both ORF13 and ORF14, we expressed
ORF13 and ORF14 in pET28a as a recombinant protein with three amino acids,
glycine-serine-serine, linker sequence in-between the two proteins. Expression
and purification were done as described above. To generate sera, 3-4 week-old
female Balb/c mice were immunized three times, intramuscularly, with 10 µg of
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purified recombinant protein (ORF13 + ORF14); all immunizations were done at
two-week intervals in the presence of alum adjuvant. Two weeks after the last
immunization, sera were collected and used for western blots against ORF13
and ORF14 coat proteins. Animal work was conducted in accordance with
Michigan Tech Institutional Animal Care and Use Committee (IACUC) guidelines.

1.3.6 Western blots
One hundred ng of purified ΦIN93 coat proteins, bacteriophage ΦIN93, and
control MS2 coat proteins were resolved on an SDS-PAGE gel and transferred to
polyvinylidene fluoride (PVDF) membranes. The membranes were then blocked
overnight with 5% non-fat milk followed by the addition of 1:1,000 dilution antiORF13 + ORF14 sera. The membranes were incubated for 2 hours at room
temperature, washed, and 1:5,000 dilution of horseradish peroxide (HRP)conjugated goat anti-mouse IgG antibodies were added for 1 hour at the same
temperature. The membranes were then washed, developed with enhanced
chemiluminescent substrate, and scanned using Luminescent Image Analyzer
(LAS-4000).
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1.4 Results
1.4.1 ORF13 and ORF14 can be successfully expressed in E. coli
To assess whether ORF13 and ORF14 coat proteins can be expressed in E. coli,
given the fact that the coat proteins are derived from a thermophilic
bacteriophage, we first generated expression vectors, pET15b-ORF14 and
pET28a-ORF13, each with complete sequences of ORF14 and ORF13,
respectively (Fig. 2). As shown in Fig. 2A, the coat proteins were successfully
expressed in C41 E. coli cells.

However, the expression level of ORF13 in

pET28a seemed to be high compared to that of ORF14 in pET15b. To assess if
the difference in expression level was due to the expression vectors used or the
genes cloned to the expression vectors, we swapped the genes in the expression
vectors by cloning ORF13 gene into pET15b and ORF14 gene into pET28a (Fig.
2B). The expression level of ORF14 from pET28a vector was still low compared
to that of ORF13 from pET15b vector (Fig. 2A), suggesting that the gene and not
the expression vector was associated with the differences in expression levels.
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Fig. 2. Expression of coat proteins, ORF13 and ORF14, in pET15b and
pET28a vectors in C41 cells. A) Plasmids pET15b-ORF14 or pET28a-ORF13
and B) plasmids pET15b-ORF13 or pET28a-ORF14 were used to transformed
C41 E. coli cells. The bacteria were grown at 37 °C and protein express was
induced with 0.5 mM IPTG. Cell pellets were lysed with 8 M Urea and loaded on
SDS-PAGE gel for analysis. Gels were stained with Coomassie blue. Arrows
indicate coat protein bands of ORF13 (18.81 KD) and ORF14 (32.01 KD). (-) is
uninduced culture and (+) is induced IPTG culture. M=Molecular weight marker.
To assess whether ORF13 and ORF14 coat proteins can be expressed in
the same bacteria, on the assumption that the two are required for assembly into
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VLPs, we co-transformed C41 cells with two different combinations of expression
vectors, pET15b-ORF14 and pET28a-ORF13 or pET28a-ORF14 and pET15bORF13. Both proteins were co-expressed in bacteria regardless of the
combinations used (Fig. 3A). However, in pET15b-ORF14 and pET28a-ORF13
combination, ORF13 was expressed at high levels compared to ORF14 (results
are similar to expression of the proteins, separately, above). In pET28a-ORF14
and pET15b-ORF13 combination, both proteins seemed to be expressed at
similar levels (with ORF14 expression slightly higher). To assess whether ORF13
and ORF14 coat proteins (complete sequences) can assemble into VLPs, TEM
analysis was conducted using co-expressed coat proteins. Unfortunately, none of
the expressed coat proteins from the plasmid combinations, pET15b-ORF14 and
pET28a-ORF13 or pET28a-ORF14 and pET15b-ORF13, assembled into VLPs.
To confirm that the purified coat proteins were proteins of interest, we did a
western blot using anti-ORF13 + ORF14 antibodies. As shown in Fig. 3B, the
antibodies reacted with both proteins as well as with our positive controls, ORF13
and ORF14, from the bacteriophage ΦIN93.
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Fig. 3. Co-expression of ORF13 and ORF14 proteins in C41 cells. A) Equal
concentrations of pET15b-ORF14 and pET28a-ORF13 (Co-1) or pET15b-ORF13
and pET28a-ORF14 (Co-2) were mixed together and the mixtures were then
used to separately transform C41 E. coli. The bacteria were grown at 37 °C and
co-protein expression was induced with 1 mM IPTG. Cell pellets were lysed with
8 M Urea and loaded on SDS-PAGE gel for analysis. Gels were stained with
Coomassie blue. Arrows indicate coat protein bands of ORF13 (18.81 KD) and
ORF14 (32.01 KD). (-) is uninduced culture and (+) is induced IPTG culture.
M=Molecular weight marker. B) Western Blots: ORF13, ORF14 and coexpressed proteins (ORF13 and ORF14) were prepared for SDS-PAGE gel and
detected by serum raised from mice immunized with ORF13 + ORF14 proteins.
Bacteriophage MS2 VLPs were used as a negative control while the purified
ORF13-ORF14 recombinant proteins were set as positive control.

1.4.2 Truncated ORF13 and ORF14 can be co-expressed and purified from
E coli
As mentioned above, ORF13 and ORF14 is 80% and 73% identical, in
terms of amino acid, to VP16 and VP17 of bacteriophage P23-77, respectively.
The 3D structure of VP16-VP17 complex has been predicted; VP16 forms a
homodimer in the complex and VP17 coat protein interacts with at least one
monomer of VP16 in the complex [34]. Given this information, we decided to
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predict the 3D structure of ORF13-ORF14 complex, based on structure of VP16VP17 complex, using SWISS-MODEL and Cn3D [35, 36]. As shown in Fig. 4, the
3D structure of ORF13-ORF14 complex is similar to that of VP16-VP17; the
software predicted the structure using only amino acids number 21-165 from
ORF13 and amino acids 46-271 from ORF14 (the same range of amino acids for
VP16-VP17 complex). Because the structure was predicted using only amino
acids 21-165 and 46-271 but not the complete sequences, we generated
truncated versions of ORF13 (aa 21-165) and ORF14 (aa 46-271) and assessed
the potential of the coat proteins to assemble into VLPs. ORF13-trunc and
ORF14-trunc were successfully expressed, as single proteins or co-expressed
proteins, regardless of whether pET15b or pET28a was used as the expression
vectors (Figs. 5A and B). Purified single-expressed ORF13-trunc coat protein but
not the single-expressed ORF14-trunc reacted with the recombinant ORF13ORF14 antibodies (Fig. 5C); these results including those of co-expressed
ORF13-trunc and ORF14-trunc are consistent with the results of coat proteins
expressed with complete sequences above (Fig. 3B).
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Fig.

4.

Three

dimensional

(3D)

structures

of

coat

proteins

of

bacteriophages ΦIN93 and P23-77. The 3D structure of ORF13-ORF14
complex (left) from bacteriophage ΦIN93 was modeled, based on sequences and
the 3D structure of VP16-VP17 complex (right; Cn3D view) from bacteriophage
P23-77 as template, using Swiss-Model software. Homodimers of ORF13
(middle) and VP16 (middle) interact with each of the two copies of ORF14 and
VP17, respectively. Both structures were modeled using amino acids 21-165
from ORF13 or VP16 and amino acids 46-271 from ORF14 or VP17 (highlighted
in gray-background in Figure 1).
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Fig. 5. Single-expression and co-expression of truncated ORF13 (ORF13-trunc)
and truncated ORF14 (ORF14-trunc) proteins in C41 cells. A) Plasmids pET15bORF14-trunc or pET28a-ORF13-trunc were used to separately transform C41 E. coli
cells and the bacteria were grown at 37 °C. Protein expression was induced with 0.5 mM
IPTG. B) Equal concentrations of plasmids pET15b-ORF14-trunc and pET28a-ORF13trunc (Co-3) or pET15b-ORF13-trunc and pET28a-ORF14-trunc (Co-4) were mixed and
used to transformC41 E. coli cells. The bacteria were grown at 37 °C and co-protein
expression was induced with 1 mM IPTG. Cell pellets were lysed with 8 M Urea and
loaded on SDS-PAGE gel for analysis. Gels were stained with Coomassie blue. Arrows
indicate protein bands, ORF13-trunc (16.06 kD) and ORF14-trunc (24.97 kD). (-) is
uninduced culture and (+) is induced IPTG culture. M=Molecular weight marker. C)

Western blots: ORF13-trunc, ORF14-trunc and co-expressed proteins (ORF13trunc and ORF14-trunc) were prepared for SDS-PAGE gel and detected by
serum raised from mice mentioned above. The phage MS2 VLPs were used as a
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negative control while the purified ORF13-ORF14 recombinant proteins and the
phage ΦIN93 were used as the positive controls.

1.4.3 Truncated ORF13 and ORF14 form structures that resemble VLPs
To assess whether the expressed coat proteins can assemble into viruslike particles, TEM analyses were conducted using purified coat proteins. As
shown in Fig. 6A, single-expressed ORF13-trunc or ORF14-trunc gave rise to
very small oval structures. The co-expressed version of the truncated coat
proteins seemed to formed structures that resemble VLPs (Fig. 6 B); their sizes
(~75 nm to ~100 nm) were closer to those of bacteriophage ΦIN93 (Fig. 6C).
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Fig. 6. Assessing the assembly of Coat proteins of single-expressed and
co-expressed ORF13-trunc and ORF14-trunc. A) TEM of purified ORF13-trunc
and purified ORF14-trunc. B) TEM of purified co-expressed truncated coat
proteins (Co-3: ORF13-trunc and ORF14 trunc expressed from pET28a and
pET15b, respectively) or (Co-4; ORF13-trunc and ORF14 trunc expressed from
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pET15b and pET28a, respectively). C) TEM of bacteriophage ΦIN93. TEM were
conducted at 25,000 X magnification.

Fig. 7. PCR amplifications of co-expressed ORF13 & ORF14 (complete gene
sequences and truncated versions). A) Induced cultures from Figure 3A (Co-1
and Co-2 with complete gene sequences) were use as templates for PCR. The
presence of ORF13 or ORF14 was tested using primers for each gene. Sizes of
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ORF13 and ORF14 are ~579 base pairs and ~876 base pairs, respectively. B)
Induced cultures from Figure 5B (Co-3 and Co-4 with truncated versions of
genes) were used as templates for PCR. The presence of ORF13 or ORF14 was
tested using primers for each gene. Neg: untransformed E. coli culture negative
control. Sizes of ORF13-trunc and ORF14-trunc are ~441 base pairs and ~684
base pairs, respectively.

1.5 Discussion
Two coat proteins, ORF13 and ORF14, from a thermophilic bacteriophage
ΦIN93 have 80% and 73% amino acid identity, respectively, with two major coat
proteins, VP16 and VP17, of thermophilic bacteriophage P23-77 [32]. While
VP16 and VP17 coat proteins have been expressed in previous studies [33, 34].
The expressions of ORF13 and ORF14 have never been explored. Here we
cloned and assessed the expression of ORF13 and ORF14 individually and in
combination (co-expression) in E. coli C41 cells with the long term-goal of
assessing the potential of the coat proteins to assemble into virus-like particles
(VLPs). ORF13 and ORF14 coat proteins were successfully expressed, as
separate proteins, in C41 cells. Moreover, the coat proteins could also be coexpressed in the same bacteria by using two plasmids that are incompatible
(pET28a and pET15b; have the same origin of replication, pBR322) by simply
applying two different selective pressures (two antibiotics resistance; kanamycin
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and ampicillin) on the bacterial cells for 24 hours. The co-expression of ORF13
and ORF14 using two incompatible plasmids are consistent with previous studies
that have shown that two proteins can be co-expressed from incompatible
plasmids by using different antibiotic to the vectors [37, 38]. While ORF13 and
ORF13 were successfully expressed (individually or together), the expression of
ORF14 in all cases was less compared to that of ORF13, regardless of whether
the protein was expressed using pET28a plasmid or pET15b plasmid. In the coexpression study, especially Co-1 with pET28a expressing ORF13 and pET15b
expressing ORF14, we initially thought the expression bacteria might only have
pET28a-ORF13 plasmid (i.e. pET15b-ORF14 plasmid might have been lost from
the bacteria due to plasmid incompatibility). To assess if both expression
plasmids were maintained in the bacteria during expression, bacterial cultures
expressing the coat proteins were induced and aliquots (equal volumes) of the
cultures were used as templates for polymerase chain reaction (PCR). As shown
in Fig. 7A, the band intensities suggest that both plasmid combinations (pET15bORF14 and pET28a-ORF13 or pET15b-ORF13 and pET28a-ORF14) were
maintained in the bacteria. These data suggest that ORF14 expression may be
normally low on the virus. This view is supported by our Western blot data using
ΦIN93 virus. In our Western blot data (Figs. 3B and 5C), ORF14 band in the lane
with positive control ΦIN93 virus is very faint compared to ORF13 band. The
view (low expression) is further supported by data from a related coat protein,
VP17 from P23-77, which is 73% identical to ORF14; in a Master’s Thesis,
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University of Jyväskylä (Finland), it was observed that VP17 was expressed at
low levels compared to VP16 (80% identical to ORF13) following co-expression
of VP17 and VP16 using a bicistronic VP16-VP17 transcription unit [39]. Taken
together, our data suggest that ORF14 is expressed at low levels compared to
ORF13. It is likely that less proportion of ORF14 may be required for viral
assembly compared to ORF13 as has been suggested for related proteins, VP17
(540 copies) and VP16 (1080 copies) in bacteriophage P23-77 [33, 34]. We
assessed whether ORF13 and ORF14 can assemble to VLPs. As mentioned in
the introduction, a mixture of VP16, VP17, and VP11 (a minor capsid protein) of
P23-77 has been shown to form complexes in vitro suggesting that these coat
proteins may form VLPs. However, a sequence in bacteriophage ΦIN93 that is
homologous to VP11 (minor capsid protein of P23-77) has not be identified,
suggesting that the capsid protein of ΦIN93 may be composed of only two coat
proteins, ORF13 and ORF14. This may be not surprising given the fact that in
some viruses (e.g. adeno-associated virus type 2), only two coat proteins out of 3
or more coat proteins are sufficient to form VLPs [4, 40]. Unfortunately, none of
the expressed ORF13 and ORF14 coat proteins (individually or together)
assembled into VLPs.
Given the fact the expressed ORF13 and ORF14 coat proteins did not
assemble into VLPs, we generated truncated forms of the proteins based on
regions of the proteins (amino acid sequence ranges) that were used by SwissModel software to predict ORF13-ORF14 structure in Fig. 4 (left). To our
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surprise, the truncated versions of the proteins (individually or co-expressed)
seemed to be expressed at low levels compared to the full-length proteins. PCR
result based on band intensities (Fig. 7B) showed that the expression plasmids
for ORF13 and ORF14 were both maintained in the bacteria. We assessed
whether the truncated versions of ORF13 and ORF14 can assemble to VLPs.
We observed structures that look like VLPs but future studies need to confirm if
these are actually ΦIN93 VLPs.
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Summary
Most of our work focused on developing HPV L2 candidate vaccines based on
bacteriophage MS2 VLP platform and we also spent time assessing the
thermostability of the candidate vaccine by using spray-freeze drying technique;
furthermore, we assessed the potential of developing a novel VLP display
platform based on a thermophilic bacteriophage ΦIN93. In chapter 1, we showed
that inserting a concatemer of two L2 peptides (HPV31 L2 20-31 and HPV16 L2
17-31) on bacteriophage MS2 VLPs does not affect the ability of MS2 coat
proteins to form VLPs. Mixed MS2-L2 VLPs (MS2 VLPs displaying the
concatemer L2 epitope and MS2 VLPs displaying a consensus L2 epitope)
elicited

antibodies

that

cross-protected/neutralized

selected

HR-HPV

pseudovirus types (HPV16, 31, 45, 58, 33 and 18), suggesting that this is an
excellent approach to achieve broader protection against more HPV types. In
chapter 2, we continued with the assessment of cross-protection of candidate
vaccine against additional HPV types (HPV35, 39, 53, and 58). We showed that
the candidate vaccine offers protection from genital infection with more HPV
PsVs (HPV53) and protection from oral infection with selected high-risk HPV
PsVs (HPV35, 39 and 58). Overall, in Chapters 1 and 2, the candidate vaccine
showed superior protection, especially with HPVs (HPV35 and HPV39)
compared to Gardasil 9. In Chapter 2, the candidate vaccine without adjuvants
was successfully spray-freeze dried into powder for thermostability test. SFD did
not affect VLP assembly and the immunogenicity. Moreover, after 60 days
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storage in room temperature, the candidate vaccine still elicited high
immunogenicity and protection against oral infection of HPV16 PsV. In the future,
more high-risk HPVs types should be tested to assess the cross-protection
potential of this candidate vaccine. Also, longer storage time such as six months
to 1 year (at room temperature or higher) should be done to assess the
thermostability of the VLPs. The longevity of immune responses of the candidate
vaccine should also be tested.
In chapter 3, we successfully co-expressed and purified full-length and truncated
coat proteins of ΦIN93 phage. VLP-like structures were observed in the coexpression of truncated coat proteins. However, this result needs to be further
confirmed. One possible way is the gold nanoparticle staining. In brief, the VLPlike structures should be immuno-stained with serum (recombinant ORF13ORF14) mentioned above in chapter 3 and then incubated with the secondary
antibodies conjugated with gold nanoparticles. If they are VLPs formed by ΦIN93
coat proteins, the VLPs-primary antibody complex will be bound by the gold
particles. This can be observed using a TEM. A positive control can be phage
ΦIN93 which is supposed to be bound properly, while a negative control can be
HPV pseudovirus 16 VLPs which is not expected to be bound by the antibody.
However, if they fail to form VLPs in E. coli, another expression system,
thermophilic bacterium (Thermus aquaticus), can be used to co-express and
assess VLP assembly. The thermophilic bacterium might have some “elements”
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to help the coat protein fold and re-assemble given the fact that this is the natural
host of phage ΦIN93.
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